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Hematopoietic stem cell transplant (HSCT) is a treatment for hematologic cancers and other 
hematologic conditions that causes severe treatment-related symptoms. The first 30 days after 
HSCT, or the acute phase, is when symptoms are most intense. During this time, the ability of 
patients to manage their symptoms, in collaboration with their health care providers, is crucial to 
reduce the distress caused by the symptoms. Self-efficacy is the person’s confidence in their 
ability to perform a behavior, such as symptom management. This body of work describes the 
concept of self-efficacy for symptom management (SESM), presents an integrated literature 
review on self-efficacy for symptom management in cancer patients, and presents results from 
research on SESM during the acute phase of HSCT. The purpose of the longitudinal, descriptive 
study was to determine changes over time and examine the relationships between SESM, 
symptom distress and physical function. The meaning of SESM from the patient’s perspective 
pre- and post-HSCT also was explored. The study established that significant changes occur over 
time in these variables and that a relationship is present between SESM, symptom distress and 
physical functional status during the acute phase of transplant. Higher SESM was associated with 
less symptom distress and increased physical function. When symptom distress was highest, 
patients felt their worst and their self-efficacy was low, which influences how symptoms are 
managed, and affects outcomes such as functional status, hospital length of stay and overall 
quality of life. Assessment of SESM early in the treatment process, followed by patient-centered 
interventions to enhance SESM, will allow patients to manage their symptoms effectively and 
improve patient outcomes. The information presented here provides a foundation for future 
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research and development of nursing interventions to enhance a person’s SESM during the acute 
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CHAPTER 1: INTRODUCTION 
Background 
 Hematopoietic stem cell transplant (HSCT), also known as bone marrow or stem cell 
transplant, is an intensive treatment for hematological cancers such as multiple myeloma, 
lymphoma, and leukemia and other hematological conditions such as sickle cell disease or 
aplastic anemia. This treatment offers the potential for disease remission, or for some patients, a 
cure. A person can receive donor stem cells from themselves (autologous) or donor stem cells 
from a sibling or unrelated donor (allogeneic). The donor type chosen is dictated by diagnosis, 
stage, and donor availability. The numbers of HSCT in the United States is increasing as more 
umbilical cord blood and haploidentical, or half-matched, donors are used (D'Souza, Pasquini, & 
X., 2016). Researchers are striving to increase survival, reduce complications, and treat persons 
who previously would not have been candidates for this aggressive treatment due to their age or 
other chronic illnesses or comorbidities (D'Souza et al., 2016). 
The HSCT process consists of several steps including evaluation of the recipient, donor 
testing and selection, conditioning chemotherapy and for some, radiation, followed by the 
infusion of stem cells (National Marrow Donor Program, 2017). Before the transplant, the 
recipient undergoes an evaluation that includes, but is not limited to, a physical exam, lung and 
cardiac function studies, laboratory testing, and a psychological exam. The patient is admitted to 
the hospital before starting the preparatory or conditioning regimen. The conditioning regimen 
consists of high dose chemotherapy, and potential total body irradiation, depending on the type of 
disease. The conditioning regimen lasts from a few hours to seven days, based on the type of 
transplant and conditioning regimen. After the conditioning regimen is complete, the stem cells 
are infused to the patient via an intravenous line. The nadir, or time when the blood counts are at 
the lowest, occurs at 7-14 days after the conditioning regimen (Anderson et al., 2007). 




platelets, and recovery of the immune system. The risk for complications is especially high during 
the nadir and prior to engraftment, and symptoms tend to peak in severity and cause the most 
distress (Anderson 2007; Bevans 2008). Patients are discharged from the acute setting after blood 
counts have recovered and post-HSCT complications have resolved (Bevans 2008). 
The phase up to 30 days after transplant is when the greatest risk for complications exists 
and physical functioning and overall quality of life (QOL) are at their lowest levels (Bevans, 
2010; Pidala, Anasetti, & Jim, 2009). This time is also when treatment-related symptoms are at 
their peak, causing distress and impacting functional status and outcomes. Symptoms occur in 
clusters, which adds to the severity and distress. Management of symptoms during this time is of 
vital importance. However, this time is also when patients are feeling their worst and may not 
have the ability to manage their symptoms or treatment regimen. Some patients are discharged 
from the acute care setting before this point and are required to self-manage their symptoms and 
post-treatment regimens along with their non-professional caregiver (Oguz, Akin, & Durna, 
2014).  
Conceptual definition of key concepts 
Symptom distress 
Symptoms are an indication of a condition that is different from normal and are important 
cues that bring problems to the attention of the caregiver (Rhodes & Watson, 1987). Because of 
the subjective nature of symptoms, they become known when the patient reports their presence. 
Distress is a global term that represents an extensive range of emotional concerns that patients 
experience and may be less stigmatizing or embarrassing to patients than using words like 
emotional or psychiatric (Holland et al., 2013; Rhodes & Watson, 1987).  
Rhodes and Watson (1987) described the meaning of symptom distress as "physical or 
mental anguish or suffering that results from the experience of symptom occurrence and/or 
perception of feeling states" (p. 243). Lenz, Pugh, Milligan, Gift, and Suppe (1997) discuss 




symptoms bother the person. Another definition provided by Holland et al. (2013) in the National 
Comprehensive Cancer Network (NCCN) guidelines is that distress is the psychological, 
emotional, social, or spiritual concern caused by symptoms that may "interfere with the ability to 
cope effectively with cancer" (p. 192). Terms that are related to distress but different include 
bother, burden, occurrence, experience, awareness, and perception (Goodell & Nail, 2005; Hsiao, 
Loescher, & Moore, 2007). Symptom distress can be related to the person's disease or treatment 
(Goodell & Nail, 2005). 
A combination of intensity, frequency, and QOL are components of the symptom 
experience that may lead to distress (Armstrong, 2003; Goodell & Nail, 2005). The most intense 
or frequently occurring symptoms are not always the most distressing to the patient (McClement, 
Woodgate, & Degner, 1997). Examples of distressing symptoms in oncology and transplant 
patients are prevalent in the literature and include fatigue, worry (anxiety), depression, lack of 
appetite, pain, sleep disturbances, diarrhea or bowel changes, dry mouth, weakness, and others 
(Anderson et al., 2007; Badger, Segrin, & Meek, 2011; Bevans, Mitchell, & Marden, 2008; 
Hefner et al., 2014; Larsen, Nordström, Björkstrand, Ljungman, & Gardule, 2003). Anxiety or 
depression can influence the amount of distress a person feels from their symptoms (Lenz et al., 
1997). Other concerns such as prognosis, disease treatment, and side effects, social or financial 
concerns or other issues impacts levels of symptom distress (Holland et al., 2013). The most 
distressing symptoms may not be the most meaningful, and meanings associated with symptoms 
may impact physical and psychological health (Armstrong, 2003). The perception of the intensity 
of the symptom may be influenced by the perceived ominous meaning of the symptom (Dodd et 
al., 2001). For example, a headache may have a different meaning in the healthy individual as 
opposed to an individual who has just completed intensive treatment for brain cancer. 
Management of Symptoms and Symptom distress 
The relationship that symptom distress has to patient outcomes in the HSCT population 




functional status, and QOL (Bevans et al., 2014; Ransom, Jacobsen, & Booth-Jones, 2006). The 
presence of symptom distress has been shown to be a predictor of survival in those with cancer 
and as a prognostic variable of long-term survival in HSCT (Bevans et al., 2014; McClement et 
al., 1997). HSCT survivors with high symptom distress had impairments in physical health, 
significantly lower mental health (p<.001) and lower health-related QOL (Bevans et al., 2014). 
Allogeneic and autologous HSCT patients have been found to have similar rates and quality of 
psychological distress (Hefner et al., 2014). HSCT patients with symptom distress are more likely 
to be non-adherent to treatment, have sleep disturbances, and anxiety and depression, which can 
lead to increased hospitalizations (Bevans et al., 2011; Rischer, Scherwath, Zander, Koch, & 
Schulz-Kindermann, 2009). Management of symptoms impacts treatment-related costs of health, 
hospitalizations and use of the health care system (Gapstur, 2007; Ryan & Sawin, 2009). Self-
management of symptoms has been shown to optimize outcomes and influence QOL and survival 
in patients with cancer (Hoffman, 2013; McCorkle et al., 2011). Management of symptoms is 
vital to the symptom experience, both for cancer patients and those who receive HSCT. 
Self-efficacy 
Self-efficacy is a person’s belief or confidence in their ability to implement behaviors to 
achieve an outcome, such as management of symptoms (Hoffman, 2013). Unless people believe 
they can have an influence on results, they are not motivated to act (Bandura, 2001). Knowledge 
and skills of disease care are needed for self-efficacy along with cognitive and affective 
processes, motivation, confidence, competence, and awareness (Hoffman, 2013; Ryan & Sawin, 
2009; White et al., in press). Self-efficacy affects self-management of symptoms as the person’s 
perception of their ability to implement interventions will have an impact on the desired outcomes 
(Hoffman, 2013). As the person's level of performance of self-management behaviors increases, 






Self-efficacy for symptom management 
Self-efficacy for symptom management (SESM) is the ability to implement behaviors to 
prevent, recognize, and relieve symptoms in patients with cancer or undergoing HSCT (White et 
al., in press). High self-efficacy leads to effective self-management behaviors, and have been 
shown to improve symptom management in chronic illness, which reduces health care 
expenditures and utilization of health care services (Novak, Costantini, Schneider, & Beanlands, 
2013). High self-efficacy in HSCT patients may lead to more effective symptom management, 
which in turn would decrease symptom distress and improve outcomes (Bevans et al., 2014).  
Theoretical Foundations 
The theoretical foundation for this body of work was drawn from a combination of 
theories by Bandura (1997), Hoffman (2013), and Lenz et al. (1997) (Figure 1). These three 
theories are based on the concepts of self-efficacy, symptom distress, and self-management of 
symptoms. Bandura’s Self-efficacy theory states that self-efficacy is what people believe they can 
do under various circumstances and that people act when they believe they can influence results 
(Bandura, 1986, 2001). Self-efficacy is the ability to perform a desired behavior and must be 
domain specific, such as symptom management. If persons perceive they are ineffective, they 
approach intimidating situations with more anxiety (Bandura, 1986). Components that may 
influence symptom distress are situational, psychological, and physiologic factors (Lenz et al., 
1997). A relationship between self-efficacy and the ability to manage symptoms has been shown 
(Hoffman, 2013). Self-efficacy impacts functional status and quality of life and reduced 
symptoms impact outcomes such as health status, quality of life and cost of health (Hoffman, 
2013; Lenz et al., 1997).  
Symptoms are a sign that there is a change in health, and are a critical component of 
health care, especially for cancer and HSCT patients. The Theory of Unpleasant Symptoms (Lenz 
et al., 1997) conceptualizes symptoms as a multidimensional experience, where symptoms occur 




suffering or discomfort, awareness of symptom importance, the need to change actions, 
frequency, intensity, quality, and duration of symptoms (Hsiao et al., 2007; Lenz et al., 1997). 
Adverse outcomes from symptom distress include readmission to the hospital after discharge, 
decreased physical functional status and decreased QOL (Bevans et al., 2014; Novak et al., 2013).  
The Theory of Symptom Self-management blends the concept of self-efficacy with 
symptom management to provide a framework for efficacy-enhancing interventions for patients 
with cancer (Hoffman, 2013). The outcomes of this theory are performance based, both functional 
and cognitive, from a person’s symptom self-management behaviors (Hoffman, 2013). These 
three theories provide a conceptual framework that includes self-efficacy, the symptom 
experience, and self-efficacy for symptom management.  
Significance 
Self-efficacy plays a critical role in the self-management of symptoms. Memory and 
concentration impairments are adverse effects of high-dose chemotherapy received during HSCT 
and have the potential to impact self-efficacy (Wu et al., 2012). Wu et al. (2012) found that better 
cognitive functioning was associated with improved self-efficacy for symptom management, 
which was then associated with less depressed mood, reduced anxiety, and better QOL. Self-
efficacy is associated with decreased symptoms and is a significant predictor of emotional and 
physical well-being and QOL after transplant (Bergkvist et al., 2015; Hochhausen et al., 2007; 
Wu et al., 2012). These studies, while different in their objectives, show that self-efficacy is 
important in the symptom management for HSCT patients. None of the studies described here, 
however, evaluated self-efficacy and its relationship to management of symptom distress during 
the acute phase of HSCT when symptom distress is at its highest levels. Liang et al. (2016) found 
that SESM impacted the relationship between symptom distress and QOL in breast cancer 
patients. While no studies were found linking self-efficacy specifically with symptom distress in 
HSCT patients, it follows that the decrease in symptom occurrence, depression, and anxiety, and 




symptom distress. Despite findings that symptom distress affects patient outcomes, the literature 
shows that targeted interventions are still lacking (Braamse et al., 2014).  
Symptom management is a critical area for clinical research outcomes as identified by the 
Oncology Nursing Society and by the National Institute for Nursing Research (Knobf et al., 2015; 
National Institute of Nursing Research, 2016). These priority areas include studies of factors that 
influence the management of symptoms and contribute to the design of personalized 
interventions.  
Research Question 
While there is research published about symptom distress and outcomes in HSCT, very 
little research has examined self-efficacy and no research is available regarding interventions to 
facilitate self-efficacy in this population. The relationship between self-efficacy and symptom 
distress in HSCT patients is not known. Research to identify needs of the HSCT patient regarding 
self-efficacy to improve symptom management during the acute phase of HSCT has the potential 
for development of patient-centered interventions. Facilitation of self-efficacy may enable 
patients to increase engagement in managing their symptoms and lead to improved outcomes.  
Purpose and Aims 
The purpose of this study was to describe the changes over time and relationships 
between SESM, symptom distress and the outcomes of physical function and length of stay 
during the acute phase, or 30 days, post-HSCT. The specific aims were:  
1. Explore the concept of SESM from the patient’s perspective at baseline and 30 days.  
2. Determine the changes over time in SESM, symptom distress, and physical function. 
3. Examine the relationships among SESM, symptom distress, and physical function.  
4. Determine if the relationships among SESM and length of stay, readmission rates, and 







 Four chapters are presented here to contribute to the understanding of SESM in adult 
patients with cancer and HSCT recipients. Chapter II analyzes the concept of SESM in cancer 
patients. Because of the scarcity of literature on SESM in HSCT patients, the concept analysis 
focused on adult patients with cancer. Chapter III provides an integrative review on SESM. 
Again, due to the scarcity of literature on SESM in HSCT patients, the review was broadened to 
include adult patients with cancer. Chapter IV reports on the relationships of SESM, symptom 
distress and outcomes in the acute phase following HSCT. Chapter V describes the meaning of 
SESM from the patient’s perspective during their HSCT experience. Chapter VI provides a 
synthesis of the previous content to inform nursing practice on SESM in adult HSCT patients and 
addresses future steps for nursing practice and research opportunities to enhance SESM in this 
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CHAPTER II: Manuscript 1 
 
Perceived Self-efficacy for Symptom Management in Cancer Patients:  




























Background: Perceived self-efficacy (PSE) for symptom management plays a key role in 
outcomes for cancer patients such as quality of life, functional status, symptom distress and health 
care utilization. Greater PSE for symptom management predicts improved performance outcomes 
including functional health status, cognitive functioning, and disease status. Definition of the 
concept is necessary for use in research and to guide development of interventions to facilitate 
PSE for symptom management in cancer patients.  
Objective: This analysis will describe the concept of PSE for symptom management in cancer 
patients.  
Methods: A database search was performed for related publications from 2006-2016. 
Publications considered to be landmark works that informed the analysis published prior to 2006 
were included. 
Findings: Defining attributes of PSE for symptom management are: cognitive processes, 
affective processes, motivation, confidence, competence, and awareness. Antecedents identified 
were presence of symptoms, performance accomplishment, verbal persuasion and presence of 
threat or fear. Consequences of the concept include symptom relief, health status, cost of care, 
quality of life and behavior performance. Clarification of concept of PSE for symptom 
management will accelerate the progress of self-management research and allow for comparison 








Implications for Practice 
• The concept of perceived self-efficacy (PSE) for symptom management in cancer 
patients is important as persons with cancer are expected to self-manage symptoms but 
few have the ability to do so.  
• The concept of perceived self-efficacy for symptom management in cancer patients has 
not been analyzed in nursing literature.  
• Patients with high perceived self-efficacy for symptom management have the potential 
for improved outcomes such as quality of life, functional status, and symptom distress.  
• Nurses are positioned to help patients to increase self-efficacy for symptom management 





















The purpose of a concept analysis is to clarify concepts by examining their structure and 
function and to expand the body of nursing knowledge (Walker & Avant, 2011). The concept of 
perceived self-efficacy (PSE) for symptom management in cancer patients is important as persons 
with cancer are expected to self-manage symptoms but few can do so (Hoffman, 2013). The 
concept of PSE for symptom management includes both PSE and symptom management.  
Self-efficacy is a key component of self-management of symptoms and is vital for 
implementation of the behaviors needed for self-management of symptoms. People are motivated 
to act only when they believe they can influence results (Bandura, 2001). Studies have shown that 
self-efficacy positively influences self-management behavior and is linked to higher quality of 
life (QOL) and improvements in health status including decreased physical and psychological 
symptoms (Lorig & Holman, 2003; Phillips & McAuley, 2013; Porter, Keefe, Garst, McBride, & 
Baucom, 2008; Torbit, Albiani, Crangle, Latini, & Hart, 2015). 
Symptom management is a key component of nursing and cancer care (Armstrong, 
2014). Cancer patients’ symptoms are frequently occurring, severe, occur in clusters (two or more 
symptoms co-occurring) and lead to symptom burden and/or distress (Barsevick, 2007; Beck, 
Towsley, Caserta, Lindau, & Dudley, 2009). As cancer survivors live longer, symptom 
management becomes important for improving health outcomes, increasing QOL, improving 
functional status, and decreasing demand for health care services; all decreasing the cost of care 
(Ryan & Sawin, 2009). Self-management of symptoms optimizes outcomes and influences QOL 
and survival in patients with cancer (McCorkle et al., 2011). The outcomes of unmanaged 
symptoms include increased symptom distress and poor prognosis along with decreased QOL, 
functional status and survival (Gapstur, 2007). 
The Oncology Nursing Society Research Agenda identified symptom management and 




also identified symptom science and self-management as priority research areas (National 
Institute for Nursing Research, 2016). Conceptual clarity will aid in these endeavors.  
Purpose 
This concept analysis defines and clarifies the concept of PSE for symptom management 
in cancer patients. Analysis of this concept will allow for conceptual clarity in research and aid in 
developing interventions to enhance self-efficacy for symptom management.  
Data sources 
‘Self-efficacy’, ‘perceived self-efficacy’, ‘symptom management’, and ‘cancer’ were 
used to search several data bases: CINAHL, Google Scholar, PubMed, MEDLINE and 
PsycINFO. Inclusion criteria were literature that related to PSE, self-efficacy, and symptom 
management in adult cancer patients, and published in English between 2006-2016. Exclusion 
criteria were duplicate publications; topics not directly related to self-efficacy and symptom 
management or adults with cancer. A manual search of references identified additional 
publications. Landmark publications published prior to 2006 that informed the concept analysis 
were included. Of the 183 titles and abstracts reviewed, 55 met inclusion criteria or were 
landmark publications. A concept analysis combining self-efficacy and symptom management 
has not been published.  
Methods 
Walker and Avant’s (2011) method was used to determine the antecedents, defining 
attributes and consequences of this concept. PSE and symptom management have been described 
previously as individual concepts (see publications in Table 1 and 2) but have not been analyzed 
together. The attributes, antecedents, and consequences from the individual concept analysis of 
PSE and symptom management were analyzed and synthesized with data gathered from the 







Definitions and uses of the concept 
 PSE is a persons’ beliefs about their capabilities to produce effects (Bandura, 1986, 
1997). Self-efficacy can be further explained as implementing behaviors that are situation or 
domain specific, with outcome expectancies dependent on the context (Hoffman et al., 2009). The 
concept of PSE deals with perceived ability, while other similar terms describe the management 
of behaviors such as self-regulation, self-care, self-monitoring, self-management, and patient 
directed monitoring (Novak, Costantini, Schneider, & Beanlands, 2013). 
For cancer patients, PSE is the person’s belief in their ability to implement behaviors to 
achieve a desired outcome, such as symptom management. Self-efficacy becomes important 
when a person chooses a plan of action, determines the degree of effort required to achieve the 
outcome, and the amount of perseverance needed to continue when it is difficult (Hoffman, 
2013). Knowledge and skills are required to implement a behavior, but self-efficacy also requires 
motivation, competence, and perseverance (see Table 1). As PSE increases, persons become 
empowered to change behaviors (Hoffman, 2013). 
Symptom management in cancer is “a dynamic and multidimensional process in which 
patients intentionally and purposefully act on and interact with the perception (or previous 
perception) of the symptom(s) to initiate activities or direct others to perform activities to relieve 
or decrease distress from and prevent the occurrence of a symptom” (Fu, LeMone, & McDaniel, 
2004, p. 68). Symptom self-management is application of strategies by an individual to relieve 
symptoms (Hsiao, Moore, Insel, & Merkle, 2014). Symptom management begins with awareness, 
presence of discomfort or suffering, identification, and assessment of symptoms from the 
persons’ perspective (Fu et al., 2004). Symptom management includes the presence of one or 
more symptoms, the symptom experience (intensity, distress, quality, temporality, appraisal), the 




that occur in clusters require different methods of management. For example, pain may 
exacerbate depression, anxiety, or fatigue, adding to the complexity of care.  
PSE for symptom self-management is the “ability to implement situation specific 
behaviors to attain established goals, expectations, or designated types of outcomes” (Hoffman, 
2013, p. E19). Hoffman further defined symptom self-management as “a dynamic, self-directed 
process of implementing behaviors that recognize, prevent, and relieve or decrease the timing 
(frequency, duration, occurrence), intensity, distress, concurrence, and unpleasant quality from 
symptoms to achieve optimal performance outcomes” (p. E19). PSE for symptom management is 
the ability to implement behaviors to prevent, recognize, and relieve symptoms in cancer patients.  
Defining attributes  
Attributes must be present if the concept exists (Walker & Avant, 2011). The attributes of 
PSE for symptom management in cancer patients are cognitive processes, affective processes, 
motivation, confidence, competence, and awareness (Figure 1). 
 Cognitive processes. Cognitive processes involve forming ideas, setting goals, and 
acting to meet them (Zulkosky, 2009). Perception of ability plays a role in learning skills, 
performing competently and perseverance (Bandura, 1997). How persons perceive and evaluate 
symptoms (cognitive appraisal) is a catalyst for a response (Hoffman, 2013). PSE for symptom 
management requires cognitive processes to acquire knowledge, competence and confidence 
related to both PSE and management of symptoms.  
Affective processes. Affective processes such as feelings of anxiety, stress, or depression 
influence PSE (Bandura, 1997; Mystakidou et al., 2010; Sato & Sumi, 2015). Symptom 
management is influenced by affective processes as symptom awareness and decisions for 
management may be altered in conditions of high emotion or distress that are present in cancer 
patients at points in the disease trajectory. Emotional reactions can change thought processes and 
actions and have a relationship with cognitive processes (Zulkosky, 2009). Both cognitive 




Motivation. Persons’ beliefs in their efficacy affects choices they make in management 
behaviors, including how much effort to expend (Bandura, 1991). Despite having the knowledge 
or ability to perform behaviors, persons may choose not to act (Zulkosky, 2009). Outcome 
expectancies are the person’s belief that an action will lead to a specific result and, in the case of 
symptom management, includes prevention or relief of symptoms (Lev, 1997). Motivation must 
be present for both PSE and symptom management.  
 Confidence. A characteristic of self-efficacy is confidence, which is the belief in the 
ability to perform a task or behavior (Robb, 2012). PSE for managing pain, fatigue and other 
symptoms is key to a person’s ability and competence to handle challenging situations. 
Confidence impacts competence and motivation and is a required attribute for PSE for symptom 
management.  
Competence. Knowledge and skills, including managing medical equipment and 
communication with providers, are required to be competent in symptom management (Ryan & 
Sawin, 2009). Competence also includes the physical ability to perform behaviors that could 
include exercising for fatigue or changing a dressing. The capability of performing actions 
required to manage symptoms is influenced by motivation, confidence, cognitive and affective 
processes and is needed for PSE for symptom management.  
 Awareness. PSE is being aware of the ability to be effective, which includes competence, 
physical ability and controlling actions (Zulkosky, 2009). Symptom awareness is being cognizant 
of a sensation, something not known, and interpreted considering the experience (Rhodes & 
Watson, 1987). Symptoms are subjective and only known when persons report their presence 
(Rhodes & Watson, 1987). Awareness of symptoms includes recognizing new needs in relation to 
symptoms and the needed response of actions for management (Fu et al., 2004). PSE for 
symptom management occurs when persons are aware of changes in their bodies, or the 
perception of abnormal feelings or symptoms, and then have the confidence, motivation, and 





 Model case. A model case is an example of a how the concept is used that incorporates 
all of the defining attributes of a concept (Walker & Avant, 2011). A woman diagnosed with 
leukemia who has undergone several rounds of chemotherapy described her self-efficacy for 
symptom management prior to her diagnosis, and in subsequent hospitalization and treatment. 
Her statement: “Since I was diagnosed with cancer, I’m more aware of my body and I pay 
attention to changes in how I feel” demonstrates cognitive processes and symptom awareness. 
She demonstrates motivation by stating “I’ll do whatever it takes to stay out of the hospital” and 
“…the more I do for myself, the more I get to stay out of the hospital, and that means everything 
to me”. She continued: “I know the symptoms of infections, I was able to monitor that pretty 
well. I check my central line for signs of infection. I had mucositis so I couldn’t eat or talk, I had 
to force myself to get pills down. I performed oral care four times a day and ate soft foods. Then 
my blood counts went up and my mucositis went away and it was better.” These statements show 
that she is competent and has the cognitive ability to manage a complex regimen. Recognizing 
changes, being aware of her body and feelings of fear demonstrate affective processes, 
multidimensionality, dynamics, and awareness. She states, “I’m confident in myself because I 
know I can’t always rely on others”, further demonstrating that she perceives herself to have self-
efficacy for symptom management.  
Contrary case. A contrary case is an example of not having self-efficacy for symptom 
management where none of the attributes are present (Walker & Avant, 2011). Patients may not 
recognize that self-efficacy is not present, and do not take steps to manage symptoms. This is the 
situation in this contrary case of a middle-aged woman with lymphoma who did not report 
developing tingling pain on the right side of her chest and upper arm. During a physical exam, the 
health care provider identified a rash with small blisters. When asked about the rash, the woman 
said, “I felt it but didn’t think it mattered, they told me to expect these things.” She said “why 




tell anybody”. These statements reflect lack of cognitive processes and motivation and lack of 
awareness that action could be taken to manage these symptoms.  
Antecedents  
Antecedents must be in place prior to occurrence of a concept (Walker & Avant, 2011). 
The antecedents of PSE for symptom management in cancer patients are presence of symptoms, 
performance accomplishments, verbal persuasion and perception of threat or fear.  
Presence of symptoms. Symptoms bring awareness of new needs followed by the 
response of patients to the needs (Fu et al., 2004). Symptoms indicate changes in biopsychosocial 
functioning, sensations or cognition and provide clinical information (Dodd et al., 2001). In 
addition to symptom presence, persons also perceive the severity and amount of distress or 
discomfort (Rhodes & Watson, 1987). How symptoms are perceived can affect the intensity of 
the symptom experience (Brant, 2016). 
Dynamic. Cancer is a dynamic disease, with remissions and recurrences possible 
(Gapstur, 2007). Symptom management includes evaluating symptoms, determining the meaning 
and the required behavior, and is affected by types of symptoms, timing (during or after active 
treatment), environment (home or hospital) and expected outcomes. Each time a symptom occurs, 
the cycle of evaluation, determining meaning and behavior is repeated (Fu et al., 2004). Changes 
in management strategies may also occur. PSE is a product of environment, cognition, affective 
processes, and physical components that are all dynamic (Hoffman, 2013). Presence of stress, 
anxiety and depression affects PSE (Bandura, 1997).  
Multidimensional. Symptom presence and the behaviors required for management are 
multidimensional, having physical, cognitive, emotional, social, and situational components 
(Armstrong, 2003; Brant, 2016; Lenz, Pugh, Milligan, Gift, & Suppe, 1997). Symptom 
management includes perception and cognition, as well as responses to experience, the illness, 
expected outcomes and environment (Fu et al., 2004). How persons perceive their symptoms and 




Performance accomplishment. Successful performance of behavior builds PSE 
(Bandura, 1997). Encouragement of performance accomplishments includes allowing persons to 
practice a behavior or use return demonstration which, when successful, promotes increased PSE 
(Zulkosky, 2009). Conversely, failure to perform a behavior may decrease PSE. Distractions, 
complexity of the task, emotional state, and expertise of the individual modeling the behavior all 
affect the ability to perform behavior (Richard & Shea, 2011). People take pride in their 
accomplishments when they believe their success is due to their own efforts and will expend 
more effort on tasks or behaviors when they believe they are proficient (Zulkosky, 2009).  
Verbal persuasion. Verbal persuasion is when someone convinces another that they 
have the capability for a behavior such as symptom management (Zulkosky, 2009). When 
persons hear encouragement, they are more likely to use greater effort (Bandura, 1997). Persons 
can be convinced that they can be successful at task performance. Verbal persuasion can be from 
health care providers, family and friends, or other patients such as in support groups.  
Presence of threat or fear. Symptoms may be perceived as a threat to individual’s 
health (Hoffman, 2013). Evaluation of symptoms involves the intensity, location, frequency and 
affective impact and the threat posed by the symptom (Dodd et al., 2001). The presence and 
experience of symptoms may bring a perception of fear and threat, determining whether it is 
dangerous or potentially disabling, which is the catalyst for initiating management activities (Fu 
et al., 2004). Interpreting symptoms as recurrence or worsening of the cancer may cause 
avoidance behavior that will negatively influence PSE (Hoffman, 2013). 
Consequences  
Consequences are a result of the occurrence of a concept (Walker & Avant, 2011). The 
consequences of PSE for symptom management in cancer patients include symptom relief, health 
status, cost of care, quality of life and performance of the management behavior.  
 Symptom relief. Low PSE for symptom management may result in poorly managed 




functional status and impact relationships and daily life (Kim, McGuire, Tulman, & Barsevick, 
2005). Other costs of unmanaged symptoms include increased health care utilization and 
interference with treatment schedules which can lead to cancer worsening (Kim et al., 2005). 
Increased PSE for symptom management Effective symptom management leads to symptom 
relief, decreased distress, and decreased symptom occurrence (Fu et al., 2004).  
Health status. Health status includes indicators such as relief or worsening of symptoms, 
functional status, symptom distress level and survival (Fu et al., 2004). Symptom occurrence is an 
indicator of health status and patient functioning. 
 Cost of care. Symptom management impacts cost of health care through use of 
resources, treatment related services, and hospitalizations (Brant, 2016; Gapstur, 2007). Cost 
benefit ratio is important in evaluating various symptom management interventions (Brant, Beck, 
& Miaskowski, 2010). Cost is another component of multidimensionality of symptom 
management. 
Quality of life. Symptom presence and effects have a negative effect on QOL including 
role performance, functional status, physical performance, cognitive functioning, delay of 
treatment, and disease status (Brant, 2016; Gapstur, 2007). Self-efficacy has been linked to 
symptom distress, psychological health, and QOL (Bergkvist et al., 2015; Hochhausen et al., 
2007; Kohno et al., 2010; Lee, Robin Cohen, Edgar, Laizner, & Gagnon, 2006; Liang et al., 2016; 
Liao et al., 2014; Wu et al., 2012). Effective symptom management leads to decreased number or 
presence of symptoms and directly impacts QOL (Fu et al., 2004). PSE for symptom management 
can lead to prevention of symptoms and increased QOL.  
 Behavior Performance. Symptom management in persons with cancer is complex. 
Persons with low PSE may experience more stress and depression and have lower motivation 
(Zulkosky, 2009). Performance of symptom management behavior requires problem solving, 
physical function mastery, and role function (Buffart et al., 2014; Fu et al., 2004). Those with 




severity of symptoms can be related to lower cognitive functioning or ineffectual management 
behaviors (Fu et al., 2004). PSE for symptom management allows persons to perform the 
behaviors needed for symptom management.  
Empirical referents 
Empirical referents are how one recognizes or determines the existence of concepts and 
are used to develop instruments to measure concepts in research (Walker & Avant, 2011). Self-
efficacy can be measured by asking a person if they have confidence in taking an action (Lorig & 
Holman, 2003). Measurement instruments that have been used in research include the general 
PSE scale (Jerusalem, Schwarzer, & Schwarzer, 1992), the Arthritis Self-Efficacy Scale (Lorig, 
Chastain, Ung, Shoor, & Holman, 1989), the Breast Cancer Self-Efficacy Scale (Champion et al., 
2013) and the Patient-Reported Outcomes Measurement Information System (PROMIS) self-
efficacy scales for managing chronic conditions (American Institute for Research, 2016). 
Instruments related to PSE for symptom management in cancer patients include the PSE for 
Fatigue Self-Management tool (Hoffman et al., 2011) and the Symptom-Management Self-
Efficacy Scale-Breast Cancer (Liang, Wu, Kuo, & Lu, 2015).  
Discussion 
Many publications exist in nursing literature regarding the broad concept of self-efficacy. 
Limited literature is published that combines PSE with symptom management in cancer patients. 
The concept characteristics described here take prior work by Bandura in the Self-Efficacy 
Theory (1997) and others and applies it to the situation of PSE for symptom management in 
cancer patients. This concept analysis also further expands upon the concepts that are in the 
Theory of Symptom Self-Management by Hoffman (2013). PSE for symptom management is 
easily influenced, positively or negatively, because of the dynamic state of cancer diagnosis and 
subsequent treatment. Presence of symptom clusters has the potential to increase the level of 




PSE for symptom management. Individuals with high PSE for symptom management may have 
decreased symptom occurrence, symptom distress and higher QOL (Porter et al., 2008).  
Implications for Nursing 
Recognizing deficits in PSE for symptom management is critical for providing overall 
care for persons with cancer. Gaps may exist between PSE and ability for symptom management. 
Persons may have high PSE but may not have the emotional, cognitive, or physical capability to 
perform needed behaviors. A person with self-efficacy for symptom management may perceive 
symptoms as less distressing. Nurses are positioned to help patients learn new behaviors for 
managing symptoms. Interventions to increase self-efficacy, which include partnering, goal 
setting, education, social support, and internet tools, can aid in making decisions for symptom 
management (Foster et al., 2016; Goldberg, Hinchey, Feder, & Schulman-Green, 2016; Lee et al., 
2006; Myall et al., 2015; Ruland et al., 2013; Schulman-Green & Jeon, 2015; Weber et al., 2007; 
Zhang et al., 2014; Zhu, Ebert, & Wai-Chi Chan, 2017). Symptom burden may be a barrier for 
implementation of PSE interventions. PSE for symptom management is an ever-changing concept 
within a dynamic cancer environment that requires changes of strategies over time. 
Conclusion 
 PSE for symptom management can be learned (Hoffman, 2013). Using individualized 
plans of care based on the attributes, antecedents and consequences provided here, nurses can 
partner with cancer patients to reduce symptom burden, facilitate effective symptom 
management, increase health status and QOL. Conceptual definition and clarity allows for future 
research initiatives and interventions. This concept should be used in further research regarding 
symptom management in cancer patients, especially in persons with complex symptomatology 
such as those with multiple co-morbid conditions, advanced disease or receiving intense 
treatments. Future research is warranted to find ways to increase self-efficacy for symptom 




























Table 1: Concept Analysis of Perceived Self-efficacy or Self-efficacy 
Author Concept Attributes Antecedents Consequences 






Reaction to event 
Interpretation of behaviors 
needed 
Judgment of capability to 
perform required behavior 
Person decides to perform 
behavior 
Person decides not to 
perform behavior 
Person performs behavior 
after verbal persuasion 
Townsend & 
Scanlan, 2011  
Self-efficacy related to 









Physiological and affective 
state 
Approach vs. avoidance 
Quality of performance 
Persistence 
Zulkosky, 2009   Self-efficacy Cognitive and 
affective processes 
























Table 2: Concept Analysis of Symptoms in cancer patients 
Author Concept Attributes Antecedents Consequences 
Armstrong, 2003   Symptom 
experience 
Symptom occurrence and distress 






















Positive and negative outcomes 
Not given Symptom status 
Quality of life 
Performance 
 





















Decreased functional status 
Lowered self-reported QOL  




Relationships of symptoms 





Presence of 2 or 
more symptoms 
Poorer physical health status 
Interference with activities 
of daily living 
Emotional distress 
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Aims: The purpose of this integrative review is to identify and assess the evidence regarding self-efficacy 
and management of symptoms and symptom distress in adults with cancer.  
Background: Self-efficacy for symptom management plays a key role in outcomes for cancer patients 
such as quality of life (QOL), functional status, symptom distress and health-care utilization.  
Design: Integrative literature review.  
Data sources: A database search was performed for publications from 2006-2017. Articles that examined 
the relationship between self-efficacy and symptom management or self-efficacy and symptom distress in 
adult cancer patients were selected for inclusion.  
Review methods: All publications were critically appraised for methodological quality. Data were 
extracted and analyzed according to the review aims and key findings. 
Results: Twenty publications met the inclusion criteria. The studies reviewed found high self-efficacy to 
be associated with low symptom occurrence and symptom distress and higher general health and QOL. 
High self-efficacy predicted physical and emotional well-being. Low self-efficacy was associated with 
higher symptom severity, poorer outcomes, and overall functioning. Presence of self-efficacy can be 
assessed using developed instruments and self-efficacy enhancing interventions are feasible and effective.  
Conclusion: This integrative review provided information on the existing literature regarding self-efficacy 
for symptom management in the cancer population. Presence of a theoretical model and validated 
instruments to measure self-efficacy for symptom management set a groundwork for needed future 








Self-efficacy for symptom management plays a key role in outcomes for cancer patients such as 
quality of life (QOL), functional status, symptom distress and health-care utilization. This integrative 
review examined 20 publications to assess current evidence regarding self-efficacy for management of 
symptoms and symptom distress in adults with cancer. Results showed that high self-efficacy is 
associated with lower symptom occurrence and distress and better general health and QOL. Nurses are 
well positioned to implement interventions to enhance self-efficacy for symptom management. Future 




This integrative review provides information on existing literature regarding self-efficacy for 
symptom management in the cancer population. High self-efficacy leads to better symptom management 
behaviors and lower symptom distress, better functioning, and overall quality of life. Groundwork is 
present in the literature to support further research into patient-centered interventions to enhance self-











Changes in screening, early detection methods, and advances in treatments have resulted in a 
decrease in overall death rates and an increase in the number of persons living with cancer in the United 
States (Jemal et al., 2017; Miller et al., 2016). Living with cancer increases the complexity of care as 
persons often have other chronic illnesses in addition, such as heart disease, diabetes, or chronic lung 
disease (Hoffman, 2013). Acute and long-term symptoms related to a cancer diagnosis are both physical 
and psychological and result from not only the disease process but also from the treatments. Symptom 
management is an important part of the plan of care for cancer patients as uncontrolled symptoms impact 
quality of life (QOL), functional status, perception of health, cost of health care, and survival (Brant, 
2016). 
Self-efficacy is a key component of self-management of symptoms and is vital for 
implementation of the behaviors needed for self-management of symptoms. People are motivated to act 
only when they believe they can influence results (Bandura, 2001). Studies have shown that self-efficacy 
positively influences self-management behavior and is linked to higher QOL and improvements in health 
status including lower physical and psychological symptoms (Lorig & Holman, 2003; Phillips & 
McAuley, 2013; Porter, Keefe, Garst, McBride, & Baucom, 2008; Torbit, Albiani, Crangle, Latini, & 
Hart, 2015). 
Symptom management is a key component of nursing and cancer care (Armstrong, 2014). Cancer 
patients’ symptoms occur frequently, in clusters (two or more symptoms co-occurring) and lead to 
symptom burden and/or distress (Fu, McDaniel, & Rhodes, 2007; Gapstur, 2007; Kim & Abraham, 
2008). Self-management of symptoms optimizes outcomes and influences QOL and survival in patients 
with cancer (McCorkle et al., 2011). The outcomes of unmanaged symptoms include higher symptom 





Self-efficacy and symptom management are key concepts that affect outcomes for cancer patients 
in all stages of treatment. Understanding self-efficacy, symptom distress and the role that symptom 
management strategies have in controlling symptoms is imperative for maintaining or potentially 
improving functional status and QOL for cancer patients. The purpose of this integrative review is to 
examine current experimental and non-experimental research as well as theoretical and empirical 
literature regarding self-efficacy and the management of symptoms and symptom distress in adults with 
cancer.  
Background 
According to Bandura’s Social Cognitive Theory (1986), self-efficacy is a person’s belief in their 
ability to implement behaviors to achieve a desired outcome, such as symptom management, and includes 
not only using the skills required to perform a behavior, but also knowing how and when to use them 
under diverse circumstances. Self-efficacy can be learned, and therefore self-efficacy for symptom 
management can be learned (Hoffman, 2013). As self-efficacy increases, persons become empowered to 
change behaviors that are vital for self-management. Unless people believe they can have an influence on 
results, they are not motivated to act (Bandura, 2001). Self-efficacy has been associated with future health 
status and must be considered when teaching symptom management behaviors (Lorig & Holman, 2003).  
Symptoms are a subjective experience that reflects a change from the normal state and are 
important cues that bring problems to the attention of the caregiver (Dodd et al., 2001). The experience of 
distress from the presence of a symptom or cluster of symptoms is the catalyst for a person to report their 
presence and seek help (Fu et al., 2007). Symptom management in cancer is “a dynamic and 
multidimensional process in which patients intentionally and purposefully act on and interact with the 
perception (or previous perception) of the symptom(s) to initiate activities or direct others to perform 
activities to relieve or decrease distress from and prevent the occurrence of a symptom” (Fu, LeMone, & 




suffering, identification, and assessment of symptoms from the persons’ perspective (Fu et al., 2004). 
Symptom management includes the presence of one or more symptoms, the symptom experience 
(intensity, distress, quality, temporality, appraisal), the effectiveness of interventions and the 
measurement of related outcomes (Brant, 2016). Symptoms often occur in clusters and require different 
methods of management, which increases the burden on the patient and their caregiver. For example, pain 
may exacerbate depression, anxiety, or fatigue, adding to the complexity of care. 
Symptom distress is a global term that represents the amount of suffering experienced by patients 
in relation to the perception of the symptoms that are present (Holland et al., 2013).  Symptom distress is 
measured by self-report and is caused by presence of symptoms along with concerns about illness or 
prognosis, disease treatment and side effects, psychosocial or spiritual issues or financial concerns 
(Holland et al., 2013). The most distressing symptoms may not be the most severe, and the inability of 
patients to manage distressing symptoms is often the reason for seeking care (Badger, Segrin, & Meek, 
2011). Symptom distress is a key area of focus for clinical interventions as it has been shown to 
negatively affect outcomes, including higher anxiety and depression, functional status and QOL 
(Anderson et al., 2007; Bevans et al., 2014).  
Self-efficacy positively influences self-management behavior and is linked to higher QOL and 
improvements in health status including lower physical and psychological symptoms (Lorig & Holman, 
2003; Porter et al., 2008). Self-management of symptoms impacts cost of health through treatment-related 
services, hospitalizations and use of the health care system (Gapstur, 2007; Ryan & Sawin, 2009). Self-
management of symptoms has been shown to optimize outcomes and influence QOL and potentially 
survival in patients with cancer (Hoffman, 2013; McCorkle et al., 2011).  
Self-efficacy for symptom management is a predictor of patient outcomes for chronic disease 
populations (Kelleher, Somers, Locklear, Crosswell, & Abernethy, 2016). The Oncology Nursing Society 




2015). The National Institute for Nursing Research also identified symptom science and self-management 
as priority research areas (National Institute for Nursing Research, 2016).  
The aim of this integrative review was to identify, assess and synthesize data from current 
experimental and non-experimental research as well as theoretical and empirical literature regarding self-
efficacy for management of symptoms and symptom distress in the adult cancer population. The concepts 
of interest are self-efficacy for symptom management in the population of adult patients with cancer and 
subpopulation pre-or post-hematopoietic stem cell transplant (HSCT). The sampling frame includes 
research studies and theoretical publications.  
Methods 
This is an integrative review of publications in the nursing literature focusing on the concepts of 
self-efficacy for symptom management and symptom distress. The methodological approach used was the 
five-stage approach from Whittemore and Knafl (2005) of problem identification, literature search, data 
evaluation, data analysis and presentation. This method was chosen as it allows for inclusion of 
experimental and non-experimental research studies as well as theoretical publications in the analysis 
A search was performed using the databases CINAHL, Cochrane Library, MEDLINE, 
Biomedical Reference Collection, PsychINFO, NIH Reporter and Google Scholar. A keyword search 
using MeSH terms included, but was not limited to self-efficacy AND symptom management, self-
efficacy, AND symptom distress, and HSCT and cancer. The initial search was limited to HSCT patients 
only. Due to the limited number of publications found, the search was widened to include the population 
of cancer patients. The search was limited to January 2006-April 2017 to capture the most recent 
literature as cancer treatment and symptom management strategies change frequently. Additional articles 
were identified manually by searching references of retrieved articles. The first author selected journal 
articles based on the inclusion and exclusion criteria. Decisions were reviewed by the second author. 




or concepts of self-efficacy for symptom management and symptom distress, and population of adult 
patients with cancer or undergoing HSCT. Exclusion criteria included pediatric population, caregivers of 
HSCT or cancer patients, and unpublished manuscripts (dissertations).  
Search Outcomes 
 Figure 1 presents a flowchart of the identification of relevant articles. The initial search yielded 
338 articles. After examining titles and abstracts in relation to the inclusion criteria and excluding 
duplicates, 35 were selected for full text review for relevance. Nine additional articles were retrieved from 
a manual search of references from full text reviews. Of these 44 articles, 24 were excluded based on 
exclusion criteria, primarily outcomes or concepts not directly related to the self-efficacy for management 
of symptoms or symptom distress. Twenty articles were selected for inclusion in this review (Table 1). 
Eighteen research studies were selected including five intervention studies and 13 descriptive studies. One 
integrative review and one theory paper were included in the review as the data presented were directly 
relevant to self-efficacy and symptoms in this population.  
Quality Appraisal 
 The selected publications were published in peer reviewed journals. The research articles were 
evaluated for quality of methodology using a quality appraisal tool developed by blending components of 
tools in published reviews from Lines, Hutton, and Grant (2016) and Guo, Whittemore and He (2011) 
(Table 2). Criteria for quality appraisal included the study design, methodology, sample, instruments, 
analysis methods and key findings. Studies that were randomized controlled trials were also evaluated 
using criteria from the Critical Skills Appraisal Programme (CASP, 2017) (Table 3). The integrative 
review article selected for inclusion was evaluated using review criteria adapted from CASP criteria 
(Table 4). The theoretical publication was evaluated based criteria from Walker and Avant (2011) (Table 





Data Abstraction and Synthesis 
 Publications were synthesized based on factors that influenced self-efficacy for management of 
symptoms and symptom distress in persons with cancer. To facilitate the synthesis, data were extracted 
into an evidence table. This supported comparison of populations, methodologies and analyses relating to 
similarities in outcomes (Table 1).  
Results 
The 20 articles reviewed were from 18 studies from the United States, Sweden, Scotland, United 
Kingdom, Taiwan, Norway, Greece, and China. The participants were patients with breast, lung, prostate, 
colorectal, gastrointestinal, or hematologic cancer or were undergoing treatment with chemotherapy or 
HSCT or had advanced cancer. Sample sizes ranged from 74 to 325 for the 17 quantitative studies and 
eight for the mixed methods study. The mean age across all studies was 57.7 years.  
The relationship between self-efficacy and symptoms is established in cancer patient populations. 
Higher self-efficacy has been associated with higher symptom management and lower symptoms 
(Bergkvist et al., 2015; Oakley, Johnson, & Ream, 2010; Porter et al., 2008). Higher self-efficacy for 
coping with symptoms was associated with greater well-being (Shelby et al., 2014). Paterson, Robertson, 
and Nabi (2015) reported a decrease in self-efficacy when symptoms significantly increased for men with 
prostate cancer. Patients low in self-efficacy reported higher levels of symptoms and symptom distress 
including pain, anxiety, fatigue, and functional well-being (Bergkvist et al., 2015; Kelleher et al., 2016; 
Mystakidou et al., 2010; Papadopoulou et al., 2017; Porter et al., 2008). Reduced symptoms, better 
performance status, and overall general health also contribute to self-efficacy (Bergkvist et al., 2015; 
Hoffman, 2013; Mystakidou et al., 2010).  
For HSCT patients, higher self-efficacy after transplant results in increased health related QOL, 
lower depression and better general health (Bergkvist et al., 2015; Hochhausen et al., 2007). Lower self-




2015). Cognitive function is a factor to consider for self-efficacy for symptom management in these 
patients as high doses of chemotherapy required for HSCT regimens may lead to impaired cognition. Wu 
et al. (2012) suggests that interventions to increase self-efficacy will reduce the negative impact of 
subjective cognitive impairment. There is an association between self-efficacy, general health, the 
occurrence of symptoms, and ability to manage symptoms (Bergkvist et al., 2015; Hochhausen et al., 
2007; Wu et al., 2012). 
Self-efficacy impacts QOL though lower symptom occurrence and distress in cancer patients 
(Hochhausen et al., 2007; Liang et al., 2016; Mystakidou et al., 2010). Liang (2016) found that self-
efficacy for symptom management mediated the association between symptom distress and QOL in breast 
cancer patients. Lower symptom distress led to better QOL through higher self-efficacy. Other 
publications support the relationship between self-efficacy and QOL in lung, prostate, breast, and 
colorectal cancer patients (Hoffman, 2013; Mosher et al., 2016; Papadopoulou et al., 2017; Porter et al., 
2008; Shelby et al., 2014; Zhang et al., 2014).  
 Instruments to measure self-efficacy should measure a person’s beliefs in their ability to perform 
the task within the situation of the study, in this case, symptom management (Bandura, 1997). There are 
validated and reliable instruments available to measure self-efficacy for various behaviors in specific 
cancer populations (Hoffman et al., 2011; Liang, Wu, Kuo, & Lu, 2015). Liang et al. (2015) developed 
and tested an instrument that measures self-efficacy in women with breast cancer and included items 
regarding communication, the severity of symptoms, managing emotional and interpersonal disturbances 
and acquiring resources while undergoing chemotherapy. Hoffman et al. (2011) developed and validated 
an instrument to measure self-efficacy for fatigue self-management for patients undergoing 
chemotherapy. These instruments are self-report measures and have the potential for use to assess self-




This review included four intervention studies designed to enhance self-efficacy. While the 
interventions varied in methodology, all resulted in improved self-efficacy (or trends) or lower symptom 
severity or distress. Zhang et al. (2014) developed a nurse led intervention that included self-efficacy 
education, management of symptoms, relaxation techniques, and health coaching. Hoffman et al. (2017) 
used an exercise and balance intervention to impact fatigue severity and found that as behavior 
performance increased, self-efficacy for the behavior improved when compared to a control group. 
Ruland et al. (2013) discussed an internet intervention that provided symptom self-management 
information and support and allowed for communication and a diary. Oakley et al. (2010) used a diary 
intervention for symptom communication and medication scheduling. These interventions show promise 
for increasing self-efficacy and symptom management behaviors and decreasing symptom distress. An 
integrative review conducted by Zhu, Ebert, and Wai-Chi Chan (2017) found that internet based programs 
moderated by healthcare providers have positive effects on self-efficacy and symptom distress in women 
with breast cancer during treatment.  
Discussion 
The publications in this review demonstrate a link between self-efficacy, management of 
symptoms and symptom distress and QOL. The presence of self-efficacy not only predicted higher 
physical and emotional well-being but also was associated with lower symptom occurrence and symptom 
distress. This, in turn, leads to better overall health and improved quality of life. Barriers such as impaired 
cognitive function must be considered when evaluating self-efficacy. While the study by Wu et al. (2012) 
described in this review discussed impaired cognitive function in those patients having HSCT, it should 
be noted that other patients who receive chemotherapy treatment are also at risk for impaired cognitive 
function (Ahles, Root, & Ryan, 2012; Cohen, Shonka, Armstrong, & Wefel, 2014). Other barriers to 
developing self-efficacy for symptom management include patients having the belief that nothing can be 




to their health care provider. However, a barrier to effective symptom management is low or lack of self-
efficacy.  
Assessment of patient’s self-efficacy for symptom management provides a guide for directing 
care interventions. Instruments are available that are short and convenient for patients to complete either 
by paper or electronic means (Kelleher et al., 2016). As demonstrated by the few intervention studies 
selected for this review, more research is needed into effective self-efficacy enhancing interventions that 
can be tailored for patients or caregivers to use for problem-solving and managing symptoms. The Theory 
of Symptom Self-Management can be used as a framework to support the development of self-efficacy 
enhancing interventions (Hoffman, 2013).  
Nurses are well positioned to assess patient’s self-efficacy and to impact the development of 
patient-centered interventions to assist patients to manage their symptoms related to cancer and treatment. 
Nurse led interventions have been shown to be feasible and effective for increasing self-efficacy and 
decreasing symptom severity and distress. These interventions include not only education regarding 
symptom management, but mechanisms for patients to communicate and discuss the presence of 
symptoms. Patients with low self-efficacy may not feel empowered to communicate the presence of 
symptoms, especially if the symptoms are related to managing emotions such as anxiety or depression, or 
seem mild in nature. Providing mechanisms for communication of symptom presence followed by 
education of how to manage those symptoms has the potential to impact distress and QOL. The few 
intervention studies available to enhance self-efficacy for symptom management in oncology patients is 
an indication that more research is needed on this topic. Focusing research on a specific phase of 
treatment such as during chemotherapy, during intensive treatment such as HSCT, or post-treatment, 
allows for the development of patient-centered interventions. 
A limitation of the research on this topic is that except for the studies from China and Taiwan, the 




HSCT patients. The lack of diversity affects the ability to generalize findings and potential development 
of interventions to other populations. Another limitation of the review findings is the variability of stages 
of illness of the participants. Studies presented in this review had participants that included those newly 
diagnosed, undergoing treatment and 1 year or more post-treatment. The studies for HSCT patients were 
conducted at one-year or later post-HSCT when the potential for symptom burden is less than during the 
acute phase of transplant. There are no publications that assess self-efficacy during the acute phase of 
HSCT when symptoms are the most intense. The cross-sectional methodology of some of the selected 
studies is also a limitation, as self-efficacy has the potential to change depending on phase of treatment 
and severity of symptoms. A limitation of this review is that the studies selected for inclusion were 
English language. There may be relevant studies published in other languages that were omitted in this 
review. Strengths of this review are the use of a framework to guide the selection of studies and analysis 
and the use of quality appraisal tools specific to the publication type. The inclusion of articles from a 
variety of countries is also a strength of the review.  
Conclusion 
Recognizing deficits and intervening to enhance self-efficacy is critical for providing overall care 
for those cancer patients with presence of symptoms or symptom distress. Targeted interventions to 
enhance self-efficacy while promoting symptom management behaviors would assist patients in 
navigating the treatment experience, decrease symptom occurrence, and improve functional status and 
QOL. Research into interventions that would achieve these goals is necessary to improve QOL for adult 













Table 1: Selected Publications 






Patients who had 
received an allogeneic 
HSCT for a 
hematological disease 
(median 5 years post-
transplant) 
Compare general health, 
symptom occurrence, and self-
efficacy long-term survivors of 
HSCT who had received either 
home care or hospital care 






No differences in general 
health, symptom occurrence or 
self-efficacy between hospital 
and home care groups 
High SE was associated with 
better general health and lower 
symptom occurrence 
(Hochhausen et 
al., 2007)  
United States; 
Leukemia patients who 
received an allogeneic 
HSCT (1-year post-
transplant) 
Examine effects of pre-HSCT 
social support, self-efficacy, and 
optimism in predicting post-




Telephone survey at 
baseline and post-
transplant 
Social support, self-efficacy 
and optimism significantly 
predicted physical and 
emotional well-being post 
HSCT  
 
(Hoffman et al., 
2009) 
United States; 
Patients with breast, 
lung, colon, and other 




of pain or fatigue 
Test a theoretical model with 
the hypothesis that physical 
functional status is predicted 
through patient characteristics, 
cancer-related fatigue, other 







Results validated the model;  
Perceived SE had a positive 
effect on functional status and 
served as a mediator between 
cancer related fatigue and 
physical functional status 
(Hoffman et al., 
2011) 
United States; 
Patients with breast, 
lung, colon, and other 




of pain or fatigue 
Describe the development and 
testing of the Perceived Self-







reliability and validity and can 
be used to measure perceived 
SE for fatigue self-





Reference Setting and sample Purpose / aim Methods Findings 
(Hoffman, 
2013) 
United States;  
Cancer patients 
 
Describe how nurses can apply 
a tested middle-range theory in 
in clinical practice to  




Nurses can use perceived SE 
enhancing symptom self-
management interventions to 
improve functional status and 
QOL of cancer patients  









Investigate effects of an exercise 
intervention to promote 
perceived self-efficacy for 
fatigue self-management   
Quantitative; 
RCT;  
Surveys in person and 
telephone pre-surgery, 
post-surgery, and 




surgery, and weeks 3 
and 6 
Intervention was feasible; 
intervention group improved 
in perceived SE for fatigue 
self-management; fatigability 
was reduced and mental and 
physical health components of 
functional performance in 
intervention group improved 
when compared to control 
group 
(Kelleher et al., 
2016) 
United States; 
Patients with breast and 
gastrointestinal cancer  
Examine how patient reported 
outcomes of SE for pain, 
function and other symptoms 
were associated with pain, 
symptom severity and distress, 






SE scores for pain and other 
symptoms correlated 
positively with pain, symptom 
severity and distress, and 
physical and psychosocial 
functioning 
Patients with lower levels of 
SE had poorer outcomes and 
functioning overall 




Women with breast 
cancer 
 
Develop and evaluate the 
reliability and validity of the 
Symptom -Management Self-
Efficacy Scale--Breast 






SMSES-BC has acceptable 
reliability and validity for 
measuring symptom-
management self-efficacy 





Reference Setting and sample Purpose / aim Methods Findings 




Outpatients with breast 
cancer  
 
Examine association between 
symptom distress and QOL; 
Propose symptom management 
SE as a mediator between 






efficacy mediated the 
association between symptom 
distress and global QOL, 
functional QOL and symptom 
QOL; Lower symptom distress 
was indirectly associated with 
better QOL through higher SE   




Lung cancer patients 
and their family 
caregivers 
Examine efficacy of a telephone 
based symptom management 




Survey at baseline, 2 
and 6 weeks 
No significant differences 
between groups in symptoms, 
SE for symptom management 
or perceived social constraints 






patients in a palliative 
care unit 
Assess the relationship and 
influence of demographic and 








SE significantly correlated 
with levels of anxiety, physical 
condition, and demographics;  
SE is influenced by 
components of anxiety, age, 
physical performance, and 
gender 




patients treated with 
oral chemotherapy and 
health professionals that 
cared for them 
 
Gain insight into the patient 
experience; develop 
understanding of complexities 
in receiving oral chemotherapy; 
investigate the use of a diary 
and the impact on self-
medication, symptom 
management adherence and 
self-efficacy  








Field notes and 
reflective diary; 
Themes of relinquishing 
control and moderating 
factors;  
Trends showed an association 
between effective symptom 










et al., 2017) 
England, Scotland, 
Northern Ireland; 
Patients with breast or 
colorectal cancer 
scheduled to receive 
adjuvant chemotherapy 
Explore changes over time in 
SE and predictive ability of 
changes in state anxiety and 





Surveys prior to 
starting chemotherapy 
and at the start of 6 
subsequent 
chemotherapy cycles 
No significant time effects for 
overall SE; 
SE significantly associated 
with decreased anxiety at all 
time points;  
Significant relationship 
between SE and health-related 
QOL at all time points 
 




Men newly diagnosed 
with prostate cancer 
To test social support theoretical 
model and detail self-




Surveys at baseline 




significantly reduced at 6 
months; 
Significant decline in QOL at 
6 months post-diagnosis 




Patients with early stage 
lung cancer and their 
caregivers  
Examine SE for managing pain, 
symptoms, and function; 
Examine associations between 






Patients low in SE reported 
significantly higher levels of 
pain, fatigue, lung cancer 
symptoms, depression, 
anxiety, and significantly 
worse physical and functional 
well-being;  
When patients and caregivers 
both had low SE, the patient 
had higher anxiety and poorer 
QOL  
(Ruland et al., 
2013) 
 
Norway;  Examine effects of an internet-
based interactive health 
communication application on 
Quantitative;  
RCT;  





Reference Setting and sample Purpose / aim Methods Findings 
Patients with breast or 
prostate cancer and 
undergoing treatment  
symptom distress, depression, 
SE, health related QOL and 
social support 
Surveys at 3, 6, 9 12 
months 
no significant differences in 
other outcomes  
(Shelby et al., 
2014) 
United States; 
Women with breast 
cancer taking adjuvant 
endocrine therapy 
Examine the relationships 
between physical symptoms, SE 
for coping with symptoms, and 






Higher SE for coping with 
symptoms was associated with 
greater functional, emotional, 
and social well-being after 
controlling for physical 
symptoms; 
SE for coping with symptoms 
moderated the relationship 
between physical symptoms 
and functional and emotional 
well- being 




HSCT survivors with at 
least moderate distress 
?̅? = 1 year 8 months 
post-HSCT 
Examine whether SE for 
symptom management mediates 
relations between subjective 
cognitive functioning and 
psychological adjustment and 









confidence in ability to 
manage common post-HSCT 
symptoms; 
Better subjective cognitive 
functioning associated with 
greater self-efficacy for 
symptom management, which 
in turn was associated with 
less depressed mood. reduced 
anxiety and better QOL  






within the last 6 months  
To test effects of a nurse led SE 
enhancing intervention 




Survey at 3 and 6 
months 
 
Intervention group had 
significant improvement in SE 
and a reduction in symptom 
severity, symptom 





Reference Setting and sample Purpose / aim Methods Findings 




in Chinese and English; 
Women with breast 
cancer undergoing 
treatment 
Synthesize studies regarding 
effectiveness of internet based 
interactive programs on 
symptom distress, social 
support, SE, QOL and 
psychological well-being  
 
Integrative review Internet based interactive 
programs moderated by health 
care professionals have 
positive effects on SE, 
symptom distress, and 
psychological well-being, but 
inconclusive effects on social 
support and QOL  
 

















Table 2: Quality Appraisal for Selected Quantitative Studies 

























































Y Y Y N Y Y Y Y Y Y Y Y 
Hochhausen 
et al., 2007 
Y Y Y N Y Y Y Y y Y Y Y 
Hoffman et 
al., 2009 
Y Y Y N Y Y Y Y Y Y Y Y 
Hoffman et 
al., 2011 
Y Y Y N Y N Y Y Y Y Y Y 
Hoffman et 
al, 2017 







Y Y Y N Unknown N Y Y Y Y Y Y 
Liang, Wu, 
Kuo, & Lu, 
2015 
Y Y Y N Unknown N Y Y Y Y Y Y 
Liang et al., 
2016 
Y Y Y N Unknown N Y Y Y Y Y Y 
Mosher et al., 
2016 
Y Y Y Y Y Y N Y Y Y Y Y 
Mystakidou 
et al., 2010 




Y Y Y Y Y Y 
Oakley, 2010 Y 
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methods 
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Y Y Y N Y N/A Y Y Y Y Y Y 
Ruland et al., 
2013 
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Wu et al., 
2012 
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Zhang et 
al., 2014 






















Did the authors 








Did the authors 
do enough to 
ensure the quality 
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publication? 
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Table 5: Quality Appraisal for Theoretical Article 
Reference 
Did origins of 
the theory 
refer to its 
initial 
development? 
Does the meaning 
relate to the 
theory’s concepts 
and how they 







Usefulness: Is the theory 
practical and helpful to 
the discipline and 





be made from 
the theory? 
Parsimony:  Can the theory 
be stated simply while still 
being complete in the 
explanation of the 
phenomenon in question? 
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CHAPTER IV: Manuscript 3 
 
Self-efficacy for Symptom Management in the Acute Phase  




















Context: Hematopoietic stem cell transplant (HSCT) is an intensive treatment associated 
with distressing treatment and disease-related symptoms that affect patient outcomes such 
as functional status and quality of life. Self-efficacy for symptom management (SESM) is 
a person’s belief in their ability to perform behaviors to prevent and relieve symptoms. 
Presence of SESM can impact symptom distress and functional status.  
Objectives: This study describes the changes over time and relationships among SESM, 
symptom distress, and physical functional status in adults during the acute phase of 
HSCT.  
Methods: Patients (n = 40) completed measures of symptom distress, SESM, and 
physical function at time points prior to, and at days seven, 15 and 30 post-transplant. 
Clinical outcomes were length of stay and number of readmissions.  
Results: Symptom distress, physical function, and SESM changed significantly over time. 
There was a significant negative relationship between symptom distress and physical 
function and between symptom distress and SESM at all time points. The lowest levels of 
SESM and physical function were at day seven when symptom distress was highest. 
Symptom distress was a moderator for the relationship between physical function and 
SESM at day 15.  
Conclusion: This is the first study to examine SESM in the acute phase of HSCT. Higher 
SESM was associated with fewer symptoms and increased physical function. Less 
symptom distress is associated with higher physical function and confidence to manage 



























Hematopoietic stem cell transplant (HSCT) is an intensive treatment option for 
some types of cancer. The HSCT process includes conditioning chemotherapy with or 
without radiation treatments, followed by infusion of stem cells, either from the patient 
themselves (autologous) or from a sibling or unrelated donor (allogeneic). Disease 
diagnosis, stage, and donor availability determine transplant type. Regardless of the type 
of transplant a person receives, treatment-related symptoms are severe and can have 
significant effects on patient outcomes such as functional status and quality of life (QOL) 
(Andersson, Ahlberg, Stockelberg, & Persson, 2011; Pidala, Anasetti, & Jim, 2009; 
Wong et al., 2010). The presence of concurrent symptoms is greater during the first 30 
days and along with other factors such as physical, psychosocial, or emotional issues 
causes symptom distress (Anderson et al., 2007; Bevans, Mitchell, & Marden, 2008; 
Cohen et al., 2012). Helping patients to manage their symptoms during the intense 
treatment period immediately after HSCT may improve the symptom experience and 
influence patient outcomes.  
Self-efficacy is the belief of a person in their ability to perform behaviors 
(Bandura, 1997). Self-efficacy for symptom management (SESM) is the ability to 
implement behaviors to prevent, recognize, and relieve symptoms in cancer patients 
(White et al., in press). SESM requires not only knowledge and skills, but also cognitive 
processes, motivation, and confidence (Hoffman, 2013; White et al., in press). The 
relationship between self-efficacy and symptom distress is not known, however, presence 
of self-efficacy has been linked to better general health, lower symptom occurrence and 




et al., 2007; Wu et al., 2012). Self-efficacy, measured prior to HSCT, significantly 
predicted physical and emotional well-being one year after HSCT (Hochhausen et al., 
2007). Self-efficacy was associated with decreased symptoms and was a significant 
predictor of emotional and physical well-being and QOL for those who were one year or 
more post-transplant (Bergkvist et al., 2015; Hochhausen et al., 2007; Wu et al., 2012).  
Patients who undergo HSCT experience high symptom burden and symptom 
distress (Bevans et al., 2008; Braamse et al., 2014). Symptoms that have been shown to 
be most distressing are both physical and psychological in nature and include fatigue, 
weakness, sleep disturbances, worry or anxiety, lack of appetite, bowel problems and 
pain (Anderson et al., 2007; Bevans et al., 2008; Cohen et al., 2012). Highest symptom 
intensity occurs between 10 and 14 days after conditioning chemotherapy is initiated and 
usually return to baseline by day 30 post-transplant (Anderson et al., 2007; Campagnaro 
et al., 2008). Symptoms usually present in clusters, and have an additive effect, 
increasing the burden on patients and their caregivers (Cleeland, 2007). Consequences of 
high symptom burden include decreased survival, depression, delay in treatment, 
increased hospitalizations, and medical costs (Cleeland, 2007; Gapstur, 2007). HSCT 
patients with high symptom distress are more likely to be non-adherent with medication 
regimens, have sleep disturbances, anxiety, and depression, which can lead to increased 
hospital length of stay (Bevans et al., 2011; Lee et al., 2005; Rischer, Scherwath, Zander, 
Koch, & Schulz-Kindermann, 2009). Stress from the HSCT process, along with symptom 
distress has been shown to impact blood count recovery and overall health in the acute 




symptom management has a negative effect on physical and mental health, functional 
status, and ultimately, QOL (Bevans et al., 2014; Cleeland, 2007; Gapstur, 2007).  
Both the Oncology Nursing Society and the National Institute for Nursing 
Research have identified symptom management as a priority for research (Knobf et al., 
2015; National Institute of Nursing Research, 2016). These priority areas include studies 
of factors that influence the management of symptoms and contribute to the design of 
personalized interventions. This study of SESM in HSCT patients aligns with these 
research priorities.  
The relationship between SESM and symptom distress in HSCT patients is 
unknown. The purpose of this study was to describe the changes over time and 
relationships among SESM, symptom distress, and the outcomes of physical function, 
readmission, and length of stay during the acute phase (30 days) post-HSCT. The specific 
aims were:  
1. Determine the changes over time in SESM, symptom distress, and physical 
functional status. 
2. Examine the relationships among SESM, symptom distress, and physical 
function.  
3. Determine if the relationships among SESM and length of stay, readmission rates, 
and functional status varied depending on the level of symptom distress. 
Methods 
Design and Participants. This was a longitudinal, descriptive, pilot study. After 
obtaining institutional review board approval (Appendix A and B), participants who were 




single center in the Midwestern U.S. Inclusion criteria were that patients were at least 19 
years old and met evaluation criteria for undergoing a stem cell transplant. Exclusion 
criteria were that the patient did not speak English or could not sign their consent.  
Hertzog (2008) suggests a sample size of 20 to 25 for single group pilot studies. 
The initial enrollment goal was 30 participants to allow for attrition. When enrollment 
exceeded expectations, IRB approval to increase enrollment was sought and obtained 
(Appendix C and D). Forty-six patients were eligible for the study. Two were excluded 
for exclusion criteria and four declined to participate. Reasons for not participating were 
“not good at answering questions” and “not interested.” The final sample was 40 
participants.  
After signing consent, participants completed paper/pencil surveys at baseline, 
which was after admission to the hospital and before beginning the conditioning 
chemotherapy regimen. Post-transplant time points were at 7, 15 and 30 days after 
transplant. A brief interview was conducted with the participant at baseline and day 30 to 
obtain the patient’s perspective on SESM during the transplant process. These results are 
reported elsewhere (White, Cohen, Berger, Kupzyk, & Bierman, under review). 
Measures. Variables measured in this study included demographic and clinical 
data, symptom distress, SESM, physical functional status, length of stay and readmission 
rates.  
Demographic and clinical data. Demographic and clinical data were collected 
from patients during baseline data collection and from the medical records. Data 
collected included gender, race, age, employment status, educational level, marital status, 




of stay for transplant admission, number of readmissions and length of stay for 
readmission within 30 days after transplant. Comorbidity scores were calculated using the 
Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI). The HCT-CI score 
measures health status prior to transplant and considers both comorbidities and age as 
prognostic factors (Sorror et al., 2014). The scores were divided into three risk groups; 
low (0-2), medium (3-4) and high (>5) with a higher score indicating a higher mortality 
risk (Sorror et al., 2005).  
Symptom distress. Symptom distress was measured using the Symptom Distress 
Scale (SDS) (McCorkle, 1987) (Appendix F). The tool is a cancer-specific, 13-item self-
report questionnaire that uses a one to five scale ranging from no distress to extensive 
distress to measure the degree of distress from 11 different symptoms that are frequently 
reported by cancer patients. The symptoms, in order of presentation on the tool, are 
nausea, appetite, insomnia, pain, fatigue, bowel pattern, concentration, appearance, 
breathing, outlook, and cough. The remaining two items in the tool assess the frequency 
of nausea and pain (McCorkle, Cooley, & Shea, 1998). A total score of 25 or greater 
indicates moderate distress while a score of 33 or greater is considered severe distress 
(McCorkle et al., 1998). Reliability and validity have been demonstrated previously 
(McCorkle et al., 1998; Stapleton, Holden, Epstein, & Wilkie, 2015). Cronbach’s alpha 
was .823 at baseline and ranged from .694 - .864 in this study.  
Self-efficacy for Symptom Management. SESM was measured using the Self-
efficacy for Managing Symptoms (SEMS) (Appendix G) and Self-efficacy for Managing 
Medications and Treatment (SEMMT) (Appendix H) instruments selected from the 




for Managing Chronic Conditions measures (American Institute for Research, 2016). The 
PROMIS tools are a collection of tools developed with funding from the National 
Institutes of Health that use item response theory to measure patient-reported outcomes 
(Gruber-Baldini, Velozo, Romero, & Shulman, 2017; Jensen et al., 2015). These are 
newly developed tools and have limited reporting in the literature. Initial calibrations 
across chronic conditions show good internal consistency and cross-sectional validity 
(Gruber-Baldini et al., 2017). Reliability estimates have not been reported for the full 
item banks.  
 The SEMS instrument has 28 questions with responses on a scale from one (not at 
all confident) to five (very confident). The instrument includes items that assess persons’ 
level of confidence to manage their symptoms in different settings including hospital and 
home and to keep symptoms from interfering with activities of life such as work, sleep, 
relationships, or recreational activities (Patient-Reported Outcomes Measurement 
Information System, 2015). Cronbach’s alpha reliability for this study was .973 at 
baseline and ranged from .965 - .987 for other time points. The SEMMT has 26 questions 
with the same scale from one to five. The items assess the person’s confidence in 
managing medication schedules, managing medications in challenging situations, 
understanding the difference between medication side effects and symptoms, and ability 
to follow a treatment plan (Patient-Reported Outcomes Measurement Information 
System, 2015). Cronbach’s alpha reliability for this study was .967 at baseline and ranged 
from .975 - .988 at other time points.  
Physical Function. Physical function was measured using the PROMIS Physical 




capability within the domains of role and physical function. Questions are rated on a 5-
point scale from “without any difficulty” to “unable to do.” This instrument has been 
used in research with persons who have cancer and was found to be valid and reliable 
across age and race-ethnic groups (Jensen et al., 2015). Jensen et al. (2015) reported the 
Cronbach’s alpha in cancer patients to be from .92 - .96. The same study also reported 
high convergent validity and discriminant validity. Cronbach’s alpha reliability for this 
study was .855 at baseline and ranged from .904 - .914 at other time points.  
Length of stay and readmission(s). Length of stay, number of readmissions and 
readmission length of stay were tracked via the medical record and by self-report of 
participants. Length of stay data were not reported for patients that died prior to or after 
30 days post-transplant.  
Data analysis  
 Descriptive statistics were obtained for all variables (means, standard deviations, 
frequency distributions and percentages). Normality tests were performed and met the 
assumptions of the statistical tests used in the data analysis in all but one case. Normality 
was examined with skew and kurtosis indicating non-normality in the SEMS instrument. 
These data were log transformed for further analysis.  
 For the first research aim, repeated measures analysis of variance (RM-ANOVA) 
and paired t-tests were used to examine how SESM, symptom distress and physical 
function changed over time. Paired samples t-tests were calculated to assess changes in 
each of the variables between adjacent time points. The second research aim used 
correlations to examine the relationship between SESM, symptom distress, and physical 




changes in symptom distress and physical function over time. For the final aim, 
interaction effects between SESM and symptom distress predicting physical function 
were examined. Interaction plots, with inputs of ±1 standard deviation to indicate low and 
high values of distress and self-efficacy, were used to interpret significant moderation of 
the effect of symptom distress on functional status, length of stay and readmission rates.  
Results 
The demographic and clinical data are presented in Table 1 and Figures 1 and 2. 
Approximately half of the sample was female, mean age of 58.27 years (SD = 8.73) at 
baseline, and the race/ethnic distribution was almost exclusively white. Mean length of 
stay was 12.84 days (SD 8.33) for both transplant types. Autologous transplant 
recipient’s average length of stay at 12 days, and allogeneic transplants had an average 
length of stay of 16 days. One person died before 30 days after transplant. The majority 
were employed full time with the remaining participants retired, on disability or 
unemployed. At least 70% had greater than a high school education and were married, 
with their spouse as their caregiver.  
Autologous transplant was the most common transplant type, and the most 
common primary disease was multiple myeloma. The highest number of participants had 
a comorbidity score in the medium risk range. Over 70% of the participants were not 
readmitted to the hospital after discharge. At baseline, the most frequently occurring 
symptoms were fatigue, pain, and insomnia (Figure 1). At days seven and 15, the most 
frequently occurring symptoms were lack of appetite, fatigue, and bowel changes. At day 




and moderate distress levels were highest at day 7 and day 15 respectively, while the 
lowest distress levels were at baseline and day 30 (Figure 2). 
The first specific aim was to determine the changes over time in symptom 
distress, SESM and physical functional status. Descriptive statistic means are presented 
in Table 2 and Figures 3 and 4. At day seven, the mean score for symptom distress 
peaked, and the means for self-efficacy and physical function were the lowest. For 
symptom distress, change over time was significant [F (1.99, 57.64) = 14.94, p < .001]. 
There was a significant linear trend (p = .001) and a significant quadratic effect (p < .001) 
indicating the slope changed over time. Dependent samples t-tests indicated a significant 
increase in symptom distress between baseline and day seven, and significant decreases 
between day seven and 15, and day 15 and 30 (Figure 3; Table 3).  
Results from both the SEMMT and SEMS instruments were used to measure 
SESM. There was a significant change in SEMMT over time [F (2.6, 75.4) = 5.318, p = 
.003]. There was not a significant linear trend, but the quadratic effect was significant (p 
= .012) indicating the slope changed over time. Paired t-tests indicated a significant 
decline between baseline and day seven, and an increase between day seven and day 15 
(Figure 4; Table 3). There was a significant change in SEMS over time [F (2.8, 80.89) = 
7.418, p < .001] with a significant linear trend (p = .023) and a significant quadratic 
effect (p = .001). Paired t-tests indicated a significant decline between baseline and day 
seven, and increased between day seven and day 15, and between day 15 and day 30 
(Figure 4; Table 3).  
There were significant changes in physical function over time [F (2.8, 76.3) = 




significant (p = .009). Paired t-tests indicated a significant decline between baseline and 
day seven. No differences were found between other adjacent time points (Figure 4; 
Table 3). 
The second specific aim was to examine the relationships between SESM, 
symptom distress and physical function. Table 4 presents correlation data. Significant 
negative relationships were found between symptom distress and physical function and 
between SESM and symptom distress at all time points. A significant positive 
relationship was found between SEMMT and SEMS at each time point. There was a 
positive relationship between SESM and physical function at all time points 
The final specific aim was to determine if the relationship between SESM, length 
of stay, readmission rates, and functional status varied depending on the level of 
symptom distress. No moderating effects of symptom distress were found at baseline, day 
7 or day 30. An interaction was found at day 15 between symptom distress and SESM 
predicting physical function (p < .01). The interaction was marginally significant at day 
seven (p = .06). In participants with low symptom distress, higher SESM was associated 
with higher physical function. In participants with high symptom distress, higher SESM 
was associated with lower physical function (Figure 5). The moderating effect of 
symptom distress on the relationship between SEMMT and physical function mirrors that 
of SEMS shown in Figure 5.  
Discussion 
 This longitudinal, descriptive study examined relationships and changes over time 
in SESM, symptom distress and physical function for adult patients receiving HSCT. 




after HSCT. The findings will now be discussed in relation to clinical data and each 
specific aim and implications for nursing practice provided. Symptoms that caused 
distress found in this sample are similar to what has been reported in other studies with 
lack of appetite, fatigue, insomnia, and bowel changes common at day 15 and lack of 
appetite, fatigue, and insomnia common at day 30 (Anderson et al., 2007; Andersson et 
al., 2011; Bevans et al., 2008; Cohen et al., 2012). These studies did not report most 
common symptoms at day seven. Bevans et al. (2008) reported levels of distress in 
allogeneic transplant patients with the majority at a low level at baseline and 43% 
moderate to severe levels at 30 days post-transplant. Levels between baseline and 30 days 
post-transplant are not reported.  
The first aim determined that there were significant changes over time in 
symptom distress which is similar to other studies where symptom distress peaked at day 
seven and returned to baseline levels by day 30 (Anderson et al., 2007; Cohen et al., 
2012; Hobfoll et al., 2015). Physical function also changed over time, which is consistent 
with studies that show HSCT patients with higher symptom distress have lower physical 
and mental health status (Anderson et al., 2007; Andersson et al., 2011; Bevans et al., 
2014).  
SESM was measured using two instruments: the SEMS and SEMMT. Using each 
tool contributed to a complete picture of SESM that included not only managing 
symptoms with medications and a treatment plan (SEMMT), but also judgment regarding 
symptom management, recognizing and managing new symptoms, and performing daily 
activities or living a normal life, despite having symptoms (SEMS). SESM was lowest 




for outcomes. Changes over time in SESM have not previously been studied during the 
acute phase of HSCT. 
  The second aim found significant relationships between SESM, symptom distress 
and physical function during the acute phase of HSCT with higher SESM associated with 
fewer symptoms and increased physical function. These findings are consistent with 
results from other studies on HSCT patients, in which high self-efficacy was associated 
with better general health and lower symptom occurrence and self-efficacy predicted 
greater physical well-being (Bergkvist et al., 2015; Hochhausen et al., 2007). However, 
the timing of these studies was between one and five years post-transplant. Wu et al. 
(2012) reported in patients who were greater than one-year post-transplant, better 
subjective cognitive functioning was associated with greater self-efficacy for symptom 
management and led to less depressed mood, reduced anxiety, and higher QOL. Other 
studies examined self-efficacy and symptoms and found those with lower levels self-
efficacy reported higher symptom severity and distress, levels of pain, fatigue and worse 
physical condition and performance (Kelleher, Somers, Locklear, Crosswell, & 
Abernethy, 2016; Mystakidou et al., 2010; Porter, Keefe, Garst, McBride, & Baucom, 
2008). These studies were in patients with cancer, not receiving HSCT and not during 
acute treatment or hospitalization. The results of this study are significant in that they 
confirm that SESM impacts symptom distress during the acute phase of transplant.  
 For the final aim, there was an interaction present between the moderator variable 
of symptom distress, SESM and physical function at day 15. In participants with low 
symptom distress, high SESM was associated with higher physical function. Having less 




may increase confidence to manage symptoms. This interaction was only present at day 
15. This may be due to symptom distress being at the highest level at day 7. When 
patients feel their worst, as they were when their symptom distress was highest at day 7, 
they may be unable to participate in symptom management activities. By day 15, 
patient’s symptom distress is starting to lessen, and physical function and self-efficacy 
are improving resulting in the moderation effects seen here. This conclusion is verified by 
the patient’s perspective as patients described feeling too poorly to participate in their 
care (White et al., under review). For example, when talking about his symptoms, one 
patient stated, “I was sicker than a dog…there was no way I could have pulled myself 
through or anything I could have done to make myself feel better.” Another patient 
stated, “it didn’t matter what I did, I just felt horrible” and “for a long time in this process 
I was not self-sufficient, and that’s tough.” As patients improve (day 15), the interaction 
between symptom distress, SESM and physical function may be more apparent and then 
return to baseline levels as symptoms lessen by day 30.   
 Evidence shows that interventions to reduce distress improve patients’ ability to 
follow treatment regimens and improve outcomes of care (Holland & Alici, 2010). 
Patients are being discharged from the acute care setting earlier and effective symptom 
management is essential. Patients are expected to manage their symptoms and treatment 
plans, but not all are able to do so. Having a plan of care that includes assessment of 
SESM before HSCT will allow for patient-centered interventions to enhance SESM and 
reduce symptom distress. Using the results from the assessment, multidisciplinary 
interventions that are patient-specific can be developed. These could include focusing on 




depression, setting goals and acting to meet them, in addition to knowledge of how to 
manage treatment regimens and communication with care providers (White et al., in 
press). The interventions would be targeted toward the patient’s need, whether it be 
coaching, finding resources, or education for the caregiver. Ideally, implantation of these 
interventions would occur when symptom distress is low, as high physical and 
psychological symptom distress is a barrier to SESM (Wu et al., 2012). 
Limitations 
This study was a single-center study with a small sample size. Most of the 
participants received autologous transplants. Allogeneic HSCT patients tend to have 
more severe symptoms and a longer recovery time (Wong et al., 2010). Another 
limitation is the lack of ethnic diversity, which is common in clinical care and HSCT 
studies (Baker et al., 2009; Schriber et al., 2017). This makes the generalization of study 
results difficult. White, non-Hispanic, and married persons tend to score self-efficacy at 
higher levels (Gruber-Baldini et al., 2017). 
Strengths 
To the author’s knowledge, this is the first study that has used the PROMIS self-
efficacy tools to measure SESM in the HSCT population. The combination of the SEMS 
and SEMMT instruments for measuring SESM provided a more comprehensive view of 
the concept. The participation rate was high with 87% of patients approached consenting 
to the study. The questionnaire completion rate was 144 out of 160 data points (90%), 
with most of the missing data due to participants being too ill to complete the surveys. 
Symptom and SESM data from these patients would have been valuable as their 




This is the first study found to examine SESM in HSCT patients and has 
established the relationship between SESM, symptom distress and functional status in the 
acute phase of HSCT and provides a foundation for future intervention research. 
Enhancing SESM during all phases of transplant, but especially when symptoms are at 
their most distressing, has the potential to improve symptom management and ultimately 
patient outcomes. For HSCT patients with severe symptoms and complex treatment 
regimens, nurses can assess and implement patient-centered interventions to enhance 
SESM. Facilitation of self-efficacy will enable patients to manage their symptoms 
effectively and lead to improved outcomes including functional status, QOL, and 















Table 1: Demographic and Clinical data (N=40) 
































































Primary Disease Acute Myelocytic Leukemia 

























































Table 2: Descriptive Statistics Means (SD) at all time points 
Instrument Baseline Day 7 Day 15 Day 30 
SDS 11.85 (6.83) 17.55 (8.20) 13.64 (7.85) 10.19 (6.17) 
Physical Function 42.06 (7.84) 36.61 (7.44) 38.61 (8.93) 40.03 (8.56) 
SEMMT 45.81 (8.63) 42.90 (8.66) 45.69 (8.60) 47.57 
(10.46) 
SEMS 47.29 (6.73) 44.48 (5.21) 46.58 (6.28) 48.75 (7.94) 
Abbreviations: SDS = Symptom Distress Scale; SEMMT = Symptom Management for 


























Table 3: Dependent Samples t-tests (p-values) at all time points 
Dependent Samples t-tests (p-values) 
Instrument Baseline – Day 7 Day 7-15 Day 15-30 Baseline-Day 
30 
SDS <.001* .003* <.001* .083 
Physical Function <.001* .187 .426 .107 
SEMMT .044* .031* .157 .430 
SEMS .008* .027* .024* .406 
Abbreviations: SDS = Symptom Distress Scale; SEMMT = Symptom Management for 


























Table 4: Correlation between symptom distress, physical function, and self-efficacy  
Correlation to SEMS scale r(p) 
  
Physical 
Function SEMMT SEMS 
Symptom Distress 
Baseline -.530** (.001) -.324* (.044) -.605** (<.001) 
Day 7 -.499** (.004) -.320 (.065) -.469** (.005) 
Day 15 -.677** (<.001) -.272 (.120) -.614** (<.001) 
Day 30 -.463** (.007) -.439* (.011) -.602** (<.001) 
Physical Function 
Baseline  .268 (.094) .367* (.020) 
Day 7  .265 (.150) .376* (.037) 
Day 15  .136 (.457) .539** (.001) 
Day 30  .331 (.060) .526** (.002) 
SEMMT 
Baseline   .541** (<.001) 
Day 7   .655** (<.001) 
Day 15   .559** (.001) 
Day 30   .757** (<.001) 
** Correlation is significant at the .01 level (2-tailed). 
* Correlation is significant at the .05 level (2-tailed). 
SEMMT = Self-efficacy for Managing Medications and Treatments; SEMS= Self-

















































































































































Figure 4. Physical Function and Self-efficacy for Symptom Management Changes over time 
 
SEMMT = Self-efficacy for Managing Medications and Treatments; SEMS = 










































Figure 5: Moderating effects at Day 15 (SEMS) 
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The Meaning of Self-efficacy for Symptom Management in the Acute Phase of Hematopoietic 





















Background: Hematopoietic stem cell transplant (HSCT) is an intensive treatment that offers the 
potential for longer life or cure for some types of cancer. HSCT is associated with decreased 
quality of life (QOL), functional status and distressing symptoms. Self-efficacy for symptom 
management (SESM) is a person’s belief in their ability to implement behaviors to manage these 
symptoms. Presence of SESM can affect symptom distress, health care utilization and post-
transplant outcomes. 
Objective: The purpose of the study was to explore the meaning of SESM in adults during the 
acute phase of HSCT.  
Methods: Interviews were conducted prior to and at 30 days post-transplant. Descriptive thematic 
analysis was performed on verbatim interview transcripts.  
Results: Themes of confidence, being responsible, and caring for mind, body, spirit were 
identified with subthemes of self-confidence, confidence in other, confidence and symptom level, 
vigilance, self-advocacy, and normalcy. Participants reported having high SESM pre-transplant, 
and having much less or no SESM when symptom distress was the most severe. 
Conclusions: This is the first study to examine the patient’s perspective of self-efficacy in the 
acute phase of HSCT. This contributes to existing literature on the concept of symptom 
management and expands nursing knowledge of SESM in patients undergoing HSCT. 
Implications for Practice: Nurses can assess SESM prior to transplant and implement 
interventions to enhance SESM when symptoms are at their most distressing after HSCT. The 
findings from this study can provide the basis for creating behavioral interventions to enhance 








 Hematopoietic stem cell transplant (HSCT), also known as a stem cell or bone marrow 
transplant, is a treatment that offers the potential for an extended length of life and cure for some 
types of cancer. HSCT is an intensive treatment that is associated with decreased health-related 
quality of life (QOL) and functional status along with distressing symptoms (Larsen, Nordstrom, 
Ljungman, & Gardulf, 2007) Patients can receive donor stem cells either from themselves 
(autologous) or from a sibling or unrelated donor (allogeneic). The type of disease the person has 
along with the stage and donor availability dictate the type of transplant. The HSCT process 
consists of evaluation testing and donor selection, intensive chemotherapy and possibly radiation 
treatments, the stem cell reinfusion (transplant), and is followed by a recovery period. The acute 
phase of HSCT, which is the first 30 days after transplant, is when the greatest risk for 
complications exists and when symptom distress is the most severe. Patients often are discharged 
from the hospital setting within 30 days after transplant and expected to self-manage symptoms. 
Self-efficacy for symptom management (SESM) is vital during this time as prevention, 
recognition and symptom relief during this time can be a complex process. 
Background 
Self-efficacy is a key component of the management of symptoms. Self-efficacy is a 
person’s belief in their ability to implement behaviors to achieve a desired outcome (Bandura, 
1986). Self-efficacy includes not only the confidence, but also the knowledge and skills, 
motivation, and competence to perform the behavior under diverse circumstances (Hoffman, 
2013). Studies have shown that cancer patients and those receiving HSCT who have high self-
efficacy experience lower levels of pain, fatigue, and psychological distress and better general 
health and QOL (Bergkvist et al., 2015; Porter, Keefe, Garst, McBride, & Baucom, 2008). Cancer 
patients with lower levels of self-efficacy have been shown to have higher levels of pain, fatigue, 
depression, anxiety and poorer functioning and overall outcomes (Kelleher, Somers, Locklear, 




Symptom management is a process that is dynamic and multidimensional (Fu, LeMone, 
& McDaniel, 2004; White et al., in press). Self-efficacy for symptom management (SESM) is the 
ability to implement behaviors to prevent, recognize, and relieve symptoms in cancer patients 
(White et al., in press). SESM can be changed or influenced, in a positive or negative way, 
because of the dynamic state of the disease process, and the intensity of the transplant process. 
SESM plays a key role in outcomes for HSCT patients as symptom management affects symptom 
distress, QOL, and health care utilization.  
Many publications describe self-efficacy in cancer patients, but limited literature has been 
published on self-efficacy in HSCT patients (Bergkvist et al., 2015; Hochhausen et al., 2007; Wu 
et al., 2012). This study fills a gap in the literature regarding the meaning of SESM for patients 
undergoing HSCT. The purpose of this study was to explore the meaning of SESM in adults 
during the acute phase of HSCT. 
Methods 
 Patients in this study were part of a longitudinal descriptive study that examined the 
relationship between SESM and symptom distress during the first 30 days after HSCT. After 
obtaining approval from the Institutional Review Board (Appendix A and B), patients who were 
receiving autologous or allogeneic transplant were recruited consecutively at a single center. 
Eligibility requirements for inclusion in the study were those receiving a transplant who are at 
least 19 years of age. Exclusion criteria included not speaking English and not being admitted to 
the hospital for the transplant. Forty-six patients were eligible for participation in the study. Two 
were excluded for exclusion criteria, and four declined to participate. Reasons for not 
participating were “not good at answering questions” and “not interested.” The final sample was 
40 participants. The portion of the study reported here used qualitative descriptive methodology 
and analysis was guided by thematic analysis (Braun & Clarke, 2006; Sandelowski, 2000; Willis, 




 After participants had signed consent forms, the principal investigator (PI) conducted 
interviews using open-ended scripted questions to ensure a standardized approach (Table 1). 
Interviews were conducted at baseline (prior to transplant) and 30 days after transplant. The 
baseline interview was conducted in person, in the participant’s hospital room shortly after 
admission, but before initiation of the transplant chemotherapy regimen. If a caregiver was 
present, they were given the option to stay for the interview. All post-transplant interviews were 
completed via telephone, except for two interviews that were completed in person. All interviews 
were digitally recorded and professionally transcribed verbatim. The PI verified the accuracy of 
the transcription. The PI performed analysis with close consultation and recommendations by the 
second author and verification by the interdisciplinary team. The researchers used the descriptive 
analysis process outlined by Braun and Clarke (2006) to identify codes and search for themes 
within the data. Themes were developed using multiple readings, examining entire transcripts, 
and underlining and labeling passages with theme labels. Themes were reviewed, defined, and 
named, and compared across factors such as the type of transplant and time of interview (pre- and 
post-transplant).  
Results 
Demographic and clinical data 
A total of 70 interviews from 40 patients were analyzed. Missing interviews were due to 
patient death before 30 days (1), too ill to participate (4) and declined the final interview (5). 
Demographic and clinical data were obtained from the participants and the electronic medical 
record. Study participants ranged in age from 29 to 72 years with a mean of 58.27 years (SD 
8.73). Eighteen (45%) were women, 22 (55%) men, and 39 (97.5%) were white. While 27 
(67.5%) were employed full-time, the remainder were retired (8, 20%), on disability (4, 10%) or 
unemployed (1, 2.5%). Educational levels were high school (10, 25%), post-secondary/vocational 
and associate’s degree (17, 42.5%), and baccalaureate or post-graduate degree (13, 32.5%). The 




Most participants received an autologous stem cell transplant (n = 29, 72.5%), and 11 
received an allogeneic stem cell transplant (related = 7, unrelated = 4). Cancer diagnoses were 
multiple myeloma (20, 50%), leukemia (10, 25%), lymphoma (9, 22.5%), and myelodysplastic 
syndrome (1, 2.5%). Comorbidity scores were calculated using the Hematopoietic Cell Transplant 
Comorbidity Index (HCT-CI), which is a measure of health status that indicates mortality risk 
after HSCT (Fred Hutchinson Cancer Research Center, 2017; Sorror et al., 2014). The score 
considers both comorbidities and age with a higher score indicating a higher mortality risk. 
Twelve (30%) of the participants were considered high risk with a score of 5 or greater, 19 
(47.5%) had a score of 3-4, and 9 (22.5%) were in the low-risk group. The average length of stay 
in the hospital after HSCT was 12.84 days (SD 8.33). Most of the participants were not 
readmitted to the hospital after discharge (29, 72.5%). Six patients (15%) were readmitted one 
time, and one patient was readmitted twice.  
Themes  
The meaning of SESM was described as confidence both in one’s self and in others. 
Confidence included levels pre- and post-transplant as symptom distress varied. Level of 
confidence was the only aspect that differed from pre-to post-transplant. Responsibility included 
vigilance and advocacy. Caring for mind, body and spirit was identified as a theme and includes 
normalcy. Themes were consistent between autologous and allogeneic transplant. Table 2 
outlines the themes, subthemes, and further description follows.  
Theme: Confidence 
Self-confidence. When asked what SESM meant to them, the participants responded in 
ways that reflected their confidence and perspectives on managing symptoms. Several 
participants described the meaning of SESM in relation to the amount of confidence they felt, 
“I’m pretty confident in my ability to care for myself”, and “I’m confident in explaining my 
symptoms maybe, to a nurse, if I have a problem and how I feel about it; if I’m anxious about it.” 




symptom side. I can describe what happened. I just don’t know why it happened or what I need to 
do to correct it.” The dynamic state of the disease and transplant process was also a factor in 
confidence, as reflected in the statements of “It’s the uneasiness of what is happening, what the 
hell is happening, you know, uncertainty. That is when I don’t say I lose my confidence; it’s 
shaken” and “Anybody who says their confidence isn’t tested is not being honest with 
themselves, I think.” A 48-year-old woman who was discharged and then developed an infection 
in her bowel described her experience as:  
My confidence at home was getting pretty drained. There wasn’t much 
left. When my doctor said he wanted to admit me, I was like almost 
relieved at that point because I knew that I wasn’t at that point taking care 
of myself the way I needed to be taken care of. 
Post-transplant participants described their sense of SESM in relation to the environment, 
whether in the hospital or at home after discharge. While some participants felt that SESM was 
no different in the hospital than at home, others felt that the hospital was too controlled. One 
person described being “micromanaged” in the hospital setting. Another described it in this way:  
You feel like you don’t really have control over your own health because 
they don’t really allow you to in a sense…take this pill when you are 
scheduled to…and this is hospital policy and we do it at this time and blah 
blah, but when you get out, you are able to make your own schedule and 
do it the way you want- still right, still 12 hours apart but maybe not at 7 
a.m. and 7 p.m., but now it’s 9 a.m. and 9 p.m. because that’s better for 
me. 
Another participant, a 61-year-old female autologous recipient, spent 14 days in the hospital post-
transplant. She discussed her sense of confidence in her SESM as being limited by the nursing 




The nurses…some of them were so over-zealous that I felt like they took 
away my sense of self-efficacy. They were just so eager to – ‘don’t do this 
without buzzing. Don’t do this.’ I know that there’s safety issues, 
understandable, and they didn’t want me to fall, because obviously I was 
weak and everything, but sometimes I just felt this sense of hovering.  
One’s environment and feelings of control have an impact on self-confidence, both pre- 
and post HSCT. Participants described feeling that they needed to take control of themselves, that 
they do not have or had lost control, or that they wanted control. Specific statements included 
“Before this happened, I was an extremely healthy 52-year-old. I’m not anymore, and now all of 
the sudden you’re in a situation where you’re out of control. Cancer controls it, you don’t” and 
“It’s very frustrating, when you lose control.”  
 Confidence in others. Another aspect of confidence is in relation to those who are caring 
for the HSCT recipients, both professional providers and non-professionals, such as spouses or 
family members. The need for, and presence of confidence in their health care team was 
expressed as, “I have a good feeling about it, mainly because of the confidence in my doctor,” 
and “I felt confident in my care team, that they were on top of it and listened to me and reacted 
properly and promptly.” Others related their confidence in relation to their support systems 
stating, “All my family and friends are here…you gotta [sic] have a support team” and “Part of 
symptom management is also relying on the support of your family.” A 66-year-old man talked 
about discussing symptoms with his wife. He described how he felt lightheaded one day and said 
“and so I collaborated with my wife on that, but if I had to think of that myself, I’d have never got 
there. So, it’s nice to have somebody like that here.”  
Confidence and symptom level. When responding to the question about how much SESM 
they had prior to HSCT, participants expressed either they had a high level or a lot (25), were 
ambiguous in their response (10), or did not give a direct answer (5). Those with high SESM 




not as certain in their response, stating, “I’m hoping I’m good” and “Now it’s getting kind of real, 
so, I don’t know.” Participants provided examples of how they had managed symptoms prior to 
transplant. These included examples of symptom recognition such as “I’ve come to a point now 
going through chemo that I recognize something’s going to happen and then I say here we go.” 
One 68-year-old female who worked as a housekeeper described that she had high SESM because 
she could tolerate symptoms stating, “A little pain is not going to bother me. It doesn’t bother me. 
I’ve been known to – I walked around with a broken arm in two places for six weeks. I just kept 
working.” 
Post-transplant level of confidence varied depending on the transplant experience and amount 
of symptom distress. For some, the experience was not as difficult as expected with comments 
such as “I thought I got along pretty good, better than I thought” and “I would say it went pretty 
smooth, things went like I expected they would have.” However, more often, participants 
described their level of confidence as low when their symptoms were the most distressing. These 
participants described their experience as: “You know you should be able to do something about 
it but you can’t”, “I didn’t have as much [SESM] as I thought I would due to the fact it affected 
me so bad”, “I tell myself I’m going to feel good, and the only time that didn’t work was when…I 
had an infection, there was no way I could have pulled myself through it”, “I would have liked to 
have done more for myself, and I was just so weak.” A 59-year-old female explained: 
You just don’t feel good and there’s not much you can do about it. Then, 
toward this last week or so, you feel better because you’re starting to feel 
better and then you can do things or set little goals for yourself… Again, 
it’s like as you felt better, then you were more confident in what you could 
do. 
A 63-year-old female who stated she had a high level of SESM prior to transplant stated, 
“Beginning before I got sick, I had a lot of confidence, but then once I got sick and got all these 




Other participants commented in similar ways saying, “I always have self-confidence that I can 
manage my own symptoms and there was a point in time there where I didn’t feel that way” and 
“When you don’t feel well, nothing’s well, and that’s kind of a broad statement, but it takes it all 
in.”  
 When describing the meaning of SESM from the post-transplant perspective, participants 
elaborated on their symptom experience. Symptom recognition and presence is key to SESM. The 
symptoms mentioned varied widely in type and severity. Most commonly discussed, in order of 
frequency, were fatigue, lack of appetite, diarrhea, having an infection and/or fever, changes in 
taste and weakness (Table 3). In addition to relating specific symptoms, some participants 
described general feelings of being unwell. A 59-year-old male who worked in a professional role 
described his experience as:  
You just sit there, and I was unable to read because I couldn’t concentrate 
from the chemo or from whatever, and they said that was normal, so I 
couldn’t read a book. I had no interest in watching TV, and I ended up just 
sitting there for days, what felt like five, six days, and I suppose I would 
doze off and on. They didn’t want me in bed. They wanted me sitting and 
up and moving because they thought that would help my recovery, and I’m 
sure it did, so I tried to stay out of bed, but I just didn’t have any interest in 
doing anything. I just kind of sat there. 
One participant described it as “Bam, and pardon my words, you feel like crap, you literally feel 
like crap…it doesn’t matter what you do, it’s not going away.” Another verbalized it as:  
It was fatigue and just an overall blah feeling. I had no pain. I really wasn’t 
nauseous. I just have never felt so bad. I can’t explain it. In all the things 
that I’ve had, I guess I always equate pain with how I feel, and this was not 
painful, but at the same time, I’ve never felt so rotten in my life, and it just 




One participant described her experience with mucositis after allogeneic transplant as:  
The worst thing was the mucositis, it was really bad. I didn’t eat, couldn’t 
talk, couldn’t do anything besides get some pills down, and that was 
because I had to force myself. I literally would cry when I took them. 
Theme: Responsibility 
 While confidence is a key component of SESM, responsibility and follow through are 
also important. Being responsible was identified as a theme as participants discussed how they 
view responsibility for care, advocacy, and symptom awareness.  
 Participants described the meaning of SESM as being responsible, which included 
understanding, communication, and follow through. Participants stated SESM is “to express what 
I feel and know what my symptoms are” and “to be able to take care of the symptoms myself, 
recognize them and maybe do treatment for them.” Two other participants noted: “I know I’m 
ultimately responsible, that I can’t expect everybody else to just do it” and “owning my response 
to the symptoms and the procedures and following through with what needs to be done.” Others 
viewed SESM looking toward the future saying, “it means to manage what I can, because I do 
what I need to do knowing that if I don’t, then it’s going to cause something down the road” and 
“if we don’t manage the symptoms, we’re not going to get better. We’re going to get worse, and 
if we get worse, we don’t have anybody to blame but ourselves.” 
Post-transplant responses were reflective of the HSCT and the responsibility of managing 
the treatment regimen. Participants gave examples of how they demonstrated SESM after HSCT, 
both before and after discharge from the hospital. Managing medications was a common 
response, with one participant stating, “I keep asking to get off some of the drugs, because I’m 





I’ve actually got a spreadsheet for my med list, for my nausea meds and 
this and that, so if I do go on them, I can keep track of what time of the 
day I took which one and all this and that. 
Vigilance. Participants talked about being aware of their bodies, changes, and symptom 
recognition both pre-and post-transplant. A 50-year-old male participant described the meaning of 
SESM to him as “I’m watching for any infection or anything, something that might be out of 
line.” Post-transplant comments included “I’m tired, but I think it’s me learning to be more aware 
of – and not only being more aware but also acting upon, knowing when I’m fatigued”, “I’ve 
stayed on top of it in terms of knowing what my body is, I take my temperature and my blood 
pressure a couple times a day, so I’m pretty comfortable knowing if something goes wrong” and 
“I ask myself - do I recognize the symptom as being a symptom or is it severe enough to report?” 
A young woman, age 29, explained, “I’m just aware; I recognize, I kept myself aware of what to 
look for and I get scared because I guess I not only have to care for myself, but I have to care for 
my kids too.” 
 Self-advocacy. Having self-efficacy for a behavior such as symptom management 
includes being able to advocate for one’s own needs. The theme of self-advocacy was repeated 
pre-and post-transplant by these participants as “It means to be sure to relate to them [health care 
team] my symptoms and keep things clarified and that both parties involved understand each 
other for the best outcome” and “I’m not afraid to ask questions to find out the answers and carry 
through with it.” 
Some participants were very explicit in their belief in their self-advocacy stating, “If I 
need to speak up for any help that I need, I’m not afraid to do that. I will self-advocate” and “I am 
my own advocate. How about that? I am my own advocate. Because you have to be able to stand 
up for yourself.” When describing how he had developed SESM, a 69-year-old man stated, “Now 
any time my body changes or something changes, I speak up right away. I used to just keep it in 




Theme: Caring for mind, body, and spirit  
 Several participants described psychological and spiritual aspects of the meaning of 
SESM in addition to the physical. Descriptions included attitude, seeking to be normal again, 
taking their mind off their symptoms, and a holistic approach, in addition to acceptance and 
coping. They described how having a positive attitude affected how they managed symptoms as 
“My ability to accept what I’ve got to deal with and the way that I approach it with my attitude”, 
“To me, it’s about having a positive attitude, I can manage my symptoms by telling myself that 
I’m going to be better”, and “I think you have to have the right attitude, which gives you the 
confidence to look forward to your journey.” One participant talked about avoiding negative 
thoughts: “I just don’t dwell on the negative. I do give myself time to grieve about issues, which I 
think is very important, but try not to go past that five-minute pity party.” Two participants talked 
about the difficulties of managing their mindset stating, “This is the hard part. The head. Keeping 
my head straight. I know the physical part is taken care of” and “Because I’ve always been a 
tough guy and just, you know, and I got real frustrated because I couldn’t take it.” A 58-year-old 
male stated post-transplant that: 
I went in there with a fighter’s attitude and I think that’s a good thing, 
because a little while there a person would usually want to give up, but I 
didn’t want to do that. I want to be around for my family. I mean, there 
was a tough time there for a bit, but I think I tried to use my positive 
mental attitude to fight through it and it made me a lot more spiritual than 
I’d ever been before. 
One participant described a holistic approach to SESM stating, “You know you can’t just do the 
medical part. You have to do the mind, the spirit, the body. You have to do it all, and I’ll never 
forget that.” Another participant stated post-transplant that “It changes you physically and it 




 Participants described symptoms that affected mind and body. One person described his 
change in appearance as “I look in the mirror, and I see no hair. That’s what I see. Hey look, a 
reminder of what you have.” Other responses included “I get moody or angry for no reason...my 
family notices this and it’s hard”, “The mental is tough, I just want it over” and “This grand finale 
is the transplant…its awful scary to me.”  
Normalcy. Seeking to be normal again is an aspect that includes psychosocial and 
spiritual in addition to the physical condition. Participants described wanting to be home or to get 
back to work or other activities that were important to them both pre-and post-transplant. 
Participants discussed being physically normal again by saying “I wanted my body back” and 
“There’s a normalcy you have to have, in order to get back to it, but you have to do certain things 
[physical therapy].” Others talked about wanting to return to activities they could do pre-
transplant such as driving: “I’m the kind of person that just wants to keep going, and this stuff’s 
kinda [sic] cramping my style,” and playing golf “I’m anxious to get going again because I golf a 
lot and I haven’t golfed in about a month and a half or two months.” Another participant 
expressed uncertainty as: “Hopefully, by the time my 100 day’s post-transplant comes around, I’ll 
be living a semi-normal life like I want, but there’s no promises.” 
Conclusions 
While there are research studies published on self-efficacy in HSCT patients (Bergkvist 
et al., 2015; Hochhausen et al., 2007; Wu et al., 2012), we were unable to find other qualitative 
research describing what self-efficacy means to patients in the acute phase of HSCT. Believing 
that SESM is present will influence the choices they make to manage symptoms, the effort they 
put forth and how they persist when there are setbacks (Bandura, 1991). Most of the participants 
felt that they had high SESM before HSCT. Several participants related that as symptom distress 
increased, self-efficacy lessened. Other studies also have shown that self-efficacy is significantly 
associated with symptom severity such as pain, anxiety, distress, and symptom severity in cancer 




time in the HSCT process when symptom management interventions are most important, and 
nursing interventions are vital to enhance or reinforce self-efficacy. Nurses should be mindful of 
and balance patients’ personality, their level of SESM, and need for control when providing for 
patient safety. Understanding individual patients’ experience will help guide nurses to provide 
more interventions when necessary and to explain the rationale for these changes.  
Other publications have discussed patients seeking normalcy at 100 days or longer after 
HSCT (Hacker, 2003; Lyons et al., 2010; Mosher et al., 2011). Mosher et al. (2011) reported 
patients seeking normal at between one and three years after transplant as they resumed work and 
social roles and Hacker (2003) discussed normalcy as a concept within QOL. Returning to normal 
is a part of psychological well-being and a way to measure recovery (Lyons et al., 2010; Whedon 
& Ferrell, 1994). Results from this study show that patients are seeking to return to normal as 
early as before HSCT and within 30 days post-transplant.  
In prior studies, physical symptoms, distress, and QOL have been determined to be key 
factors in the experience both pre-and post-transplant (Mosher, Redd, Rini, Burkhalter, & 
DuHamel, 2009; Pidala, Anasetti, & Jim, 2009; Smith, Hobson, & Haig, 2016). Symptoms 
frequently reported after HSCT include fatigue, worry, appetite changes, feeling sick, insomnia 
and bowel changes (Anderson et al., 2007; Bevans, Mitchell, & Marden, 2008; Campagnaro et 
al., 2008; Stapleton, Holden, Epstein, & Wilkie, 2015). Psychological distress that includes 
anxiety is also common in HSCT recipients (Baliousis, Rennoldson, & Snowden, 2015; Mosher 
et al., 2009). These findings are supported here by participants comments about anxiety, worry 
and being scared. Assessment pre-transplant to identify patients who may be more 
psychologically vulnerable or have anxiety or depression is important as they are at risk for 
poorer outcomes and longer length of hospital stay (Cooke, Gemmill, Kravits, & Grant, 2009). 
The patients in this sample highlighted the importance of health care providers providing holistic 
care. Variability in reactions to the HSCT process and symptom burden between patients has 




treatment toxicities and other factors (Bevans et al., 2008; Campagnaro et al., 2008; Dahan & 
Auerbach, 2006). The themes and interview excerpts presented here confirm the findings from 
these other studies, add the concept of self-efficacy to the discussion, and give voice to the patient 
perspective.  
Interventions have been developed to enhance self-efficacy in cancer patients (Hoffman 
et al., 2017; Zhang et al., 2014; Zhu, Ebert, & Wai-Chi Chan, 2017). Hoffman et al. (2017) 
developed an intervention to increase self-efficacy for the management of fatigue. Other 
interventions include a telephone based symptom management intervention, use of a diary, an 
internet-based health communication application, and a nurse intervention that included 
education, relaxation techniques for symptom management and health-coaching sessions (Mosher 
et al., 2016; Oakley, Johnson, & Ream, 2010; Ruland et al., 2013; Zhang et al., 2014). SESM 
enhancing interventions specifically for transplant patients have not been developed but should be 
holistic and developed mutually with the patient to ensure strategies that are individualized to 
patient needs and personality traits.  
 Limitations of this study include that themes were not validated with participants after the 
analysis was completed, however, an interdisciplinary team verified the themes. A second 
limitation is missing data from patients who were too ill or in the intensive care unit to complete 
the final interview at 30 days post-transplant. The perspective of these patients, if they later 
recovered enough to participate in an interview, would have been valuable as their symptom 
experience was likely more severe and longer lasting than the other participants. Another 
limitation is that the sample is from one center, lacks ethnic and education diversity and so results 
may be different in other locations.  
Implications for Practice 
Nurses can help patients enhance their SESM. The findings from this study provide the 
basis for creating and implementing behavioral interventions to enhance SESM. Patients’ 




confidence related to symptom distress are important findings to use when developing 
interventions. Assessing patient’s SESM before HSCT to determine their needs for symptom 
management will aid in the development and implementation of education or problem-solving 
strategies to enhance symptom management when it is needed. Being responsible for behaviors, 
being vigilant of changes, and speaking up when symptoms arise also are important topics to 
include in interventions. Recognizing when patients are at risk for increased symptom distress 
and decreased self-efficacy is important for timing of interventions. Patients with low SESM are 
at risk for higher symptom distress and poorer overall outcomes (Kelleher et al., 2016).6 Patients 
with high SESM that results in more effective symptom management have the potential for 
improved outcomes such as higher QOL and functional status and lower symptom distress 
(Bergkvist et al., 2015; Hochhausen et al., 2007; Hoffman, 2013). These findings add the patient’s 







Table 1. Scripted Interview Questions 
Baseline 
1. What does self-efficacy for symptom management mean to you? 
2. How much self-efficacy do you feel you have for symptom management?  
3. Can you give examples? 
30 days Post-transplant 
1. How much self-efficacy did you have for managing your symptoms during the last 30 
days? 
2. Can you give examples? 

























Table 2. Themes and Subthemes 
Confidence 
   Self-confidence 
   Confidence in others 
   Confidence and symptom level 
Responsibility 
   Vigilance 
   Self-advocacy    
Caring for mind, body, spirit 
























Table 3. Post-transplant Signs and Symptoms (in order of frequency discussed) 
Discussed by > 5 participants Discussed by 3-4 participants Discussed by 1-2 participants  
Fatigue 
Lack of appetite 
Diarrhea 
Infection/fever 
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CHAPTER VI: DISCUSSION 
Summary 
The concept analysis, literature review and research results presented in this dissertation 
add to existing literature on self-efficacy for symptom management (SESM) in the adult 
hematopoietic stem cell transplant (HSCT) patient population. This research study establishes the 
need for assessment of SESM prior to the transplant process and for the development and 
implementation of patient-centered interventions to enhance SESM. The results of this study 
showed a significant relationship between symptom distress, SESM and physical function (health 
status) as was described in the conceptual model in Chapter I.  
Chapter II provided an analysis of the concept of perceived SESM in cancer patients 
using the Walker and Avant (2011) method and included the definition, attributes, antecedents, 
and consequences of perceived SESM. Perceived SESM is how the patient views their ability to 
implement behaviors to prevent, recognize, and relieve symptoms (White et al., in press). 
Definition of the concept is necessary for research and guides future intervention development.  
The concept analysis described the concepts of self-efficacy and symptom management. 
These concepts have been analyzed separately in nursing literature; however, this is the first 
analysis of the concept of SESM. Constructed cases, both a model and a contrary case, 
demonstrated how the concept is operationalized in patients with cancer. The attributes of SESM 
are cognitive processes, affective processes, motivation, confidence, competence, and awareness. 
Antecedents are the presence of symptoms, performance accomplishment, verbal persuasion and 
presence of threat or fear. Consequences of perceived SESM are symptom relief, health status, 
the cost of care, quality of life (QOL), and behavior performance.  
Chapter III presented an integrative literature review that examined self-efficacy and 
management of symptoms and symptom distress in patients with cancer. The review included 20 
articles, including intervention and descriptive research, one integrative review and one theory 




HSCT patients; all three were studies conducted with patients who were at one year or longer 
post-HSCT (Bergkvist et al., 2015; Hochhausen et al., 2007; Wu et al., 2012). Results of the 
review showed a relationship exists between self-efficacy and symptoms in cancer patients, with 
high self-efficacy leading to better symptom management and lower symptom distress.  
 The concept analysis presented in Chapter II and the literature review in Chapter III 
supported and expanded upon the theoretical foundations and conceptual relationships discussed 
in Chapter I. Chapters II and III also provided the foundation for the research presented in 
Chapters IV and V. The concept analysis and literature review results established the conceptual 
definition and the presence of a relationship between self-efficacy and symptoms in cancer 
patients and HSCT patients one year or more post-transplant. What remained unknown was the 
relationship between these concepts in the HSCT population within the first 30 days post-
transplant. Chapter IV described the longitudinal, descriptive research study methodology and 
results and Chapter V describes the patient’s perspective of SESM.  
The study purpose was to describe the changes over time and relationships among SESM, 
symptom distress, and the outcomes of physical function and length of stay during the acute 
phase, or 30 days post-HSCT. The specific aims were:  
1. Explore the concept of SESM from the patient’s perspective at baseline and 30 days.  
2. Determine the changes over time in SESM, symptom distress, and physical function. 
3. Examine the relationships among SESM, symptom distress, and physical function.  
4. Determine if the relationships among SESM and length of stay, readmission rates, and 
functional status varies depending on the level of symptom distress. 
Demographic and clinical data were similar to what was found in other studies in HSCT 
patients (Bevans, Mitchell, & Marden, 2008; Cohen et al., 2012; Wu et al., 2012). Symptom 
experience and timing was also comparable to those reported in other studies (Anderson et al., 
2007, Cohen et al., 2012). For the first aim, significant changes over time were found in all 




among symptom distress, SESM, and physical function at all time points for the second aim. For 
the final aim, physical function and SESM varied depending on the level of symptom distress at 
day 15. Overall, higher SESM was associated with fewer symptoms and increased physical 
function while less symptom distress was associated with increased physical function and SESM. 
This study established a relationship between SESM and symptom distress, specifically during 
the phase of HSCT when symptom distress is highest.  
Chapter V described the meaning of SESM from the perspective of patients both before 
and after HSCT. Themes of confidence, responsibility and caring for mind, body, and spirit were 
described by study participants along with subthemes of self-confidence, confidence in others, 
confidence and symptom level, vigilance, self-advocacy, and normalcy. These themes related to 
the findings of the concept analysis such as confidence (self and others), cognitive processes 
(self-advocacy), affective processes and motivation (mind, body, spirit), awareness (vigilance), 
the presence of symptoms (symptom level), and symptom relief (normalcy). These findings 
validate the concept analysis and give voice to the patient’s experience.  
Practice and Research Implications 
 The presence of SESM in cancer and HSCT patients is vital for optimal patient outcomes. 
Because a relationship exists between SESM, symptom distress, and physical function, 
enhancement of SESM has the potential to reduce symptom distress and improve patient 
outcomes. SESM can be learned, which creates an opportunity for nursing intervention.  
SESM should be assessed at the earliest opportunity after treatment for cancer is begun. 
Instruments have been developed and tested to assess self-efficacy in survivors with breast cancer 
(Champion et al., 2013), SESM in patients with breast cancer (Liang, Wu, Kuo, & Lu, 2015) and 
for self-efficacy for fatigue management (Hoffman et al., 2011). For other patient populations or 
general symptom management, assessment can be done briefly and efficiently with the Patient-
Reported Outcomes Measurement Information System (PROMIS) self-efficacy scales for 




(Patient-Reported Outcomes Measurement Information System, 2015). SESM can be assessed 
using the Self-efficacy for Managing Symptoms Short Form 8a (Figure 1) and Self-efficacy for 
Managing Medications and Treatments Short Form 8a (Figure 2). Computer adaptive testing 
delivers questions based on patient’s response to a previously administered question.  
Educational or problem-solving strategies that are patient specific can be developed using 
results from the assessment. For example, if patients respond that they are not confident in listing 
their medication names or schedule, remembering to take medications as prescribed, or finding 
the information they need to manage symptoms, a patient-centered intervention can be developed. 
If persons respond that they are not confident in understanding the differences between symptoms 
and side effects of medication, education can be tailored that contrasts signs and symptoms of 
potential complications of treatment (i.e. fever, infection, mucositis) with the adverse effects of 
the persons’ medications. The assessment finding would guide the multidisciplinary intervention, 
which will be targeted toward the patient need, whether it be coaching, education, or finding 
resources. Multi-disciplinary involvement is critical as needs for SESM include expertise from 
nurses as well as pharmacists, physical therapists, social workers, case managers, or cognitive 
behavioral therapists. Administration of these interventions should occur when symptom burden 
or distress is low, as the presence of high physical and psychological symptom distress is a barrier 
to SESM (White, Kupzyk, Berger, Cohen, & Bierman, in process; Wu et al., 2012).  
 SESM plays a key role in outcomes for patients in all stages of treatment for cancer, 
including HSCT. This body of work lays the foundation for assessment and development of 
patient-centered intervention development. Future research should test the outcomes of these 
interventions in relation to the presence of symptom distress, physical functional status, use of 
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Self-efficacy for Symptom Management in Stem Cell Transplant Patients 
Demographic and Clinical Data Collection Tool 
(Collected from Electronic Medical Record) 
Subject ID _________________________ 
1. Age__________________________________________ 
2. Gender      M  / F    
3. Race __________________________________________ 
4. Ethnicity _______________________________________ 
5. Employment status  
a. Full time    / Part time /  Retired  / Disability / Unemployed  
b. If unemployed or disability  – prior employment ___________________ 
6. Marital status   Married   / Single /  Widowed / Divorced 
7. Family Caregiver   Y / N  
8. Primary Disease _________________________________ 
Location ________________________________ 
Stage ___________________________________ 
9. Transplant type (circle one) 
a. Autologous  / Related Allogeneic  / Unrelated Allogeneic  / Cord Blood 
10. Conditioning Regimen ______________________________ 






































PROMIS Item Bank v1.0 - Self-Efficacy for Managing Symptoms 
Please rate your CURRENT level of confidence in managing your health conditions by 
filling in one box per row. Consider all of your health conditions and all of your symptoms 
in your responses to the questions. If a question is not something you have experienced, 
choose an answer based on similar experiences. 
 
 

































       
SEMSX002 
I can reduce my 













       
SEMSX003 
I can control my 













       
SEMSX004 
I can control my 
symptoms by using 
















       
SEMSX005 I can do something 

















       
SEMSX006 
I can do something 














       
SEMSX007 
I can manage 













       
SEMSX008 
I can manage my 













       
SEMSX009 
I can manage my 













       
SEMSX010 














       
SEMSX011 
I can work with my 













       
SEMSX012 
I can manage my 
symptoms as well as 




















I can keep my 
symptoms from 













       
SEMSX014 















       
 
 
CURRENT level of 
confidence… 
 
I am not 
at all 
confident 













I can keep my 
symptoms from 
interfering with the 
work I need to do











       
SEMSX016 
I can keep my 
symptoms from 
interfering with my 
recreational 
activities













       
SEMSX017 
I can keep my 
symptoms from 
interfering with my 
personal care
















I can enjoy things, 
despite my 
symptoms











       
SEMSX019 
I can still 
accomplish most of 
my goals in life, 
despite my 
symptoms











       
SEMSX020 
I can live a normal 
life, despite my 
symptoms











       
SEMSX021 
I can be physically 
active, despite my 
symptoms











       
SEMSX022 
I can maintain my 
sense of humor, 
despite my 
symptoms











       
SEMSX023 
I can recognize 
when my 
symptoms change











       
SEMSX024 
I know what to do 
when my 
symptoms worsen











       
SEMSX025 
































 ...............................  
       
SEMSX026 
I can manage my 
symptoms when I 
am in an unfamiliar 
place











       
SEMSX027 
I can find the 
information I need 
to manage my 
symptoms











       
SEMSX028 
I can manage my 
symptoms when I 
am tired
















PROMIS Item Bank v1.0 - Self-Efficacy for Managing Medications and 
Treatments 
Please rate your CURRENT level of confidence in managing your medications and 
other treatments by filling in one box per row. Consider all of your health conditions 
and all of your symptoms in your responses to the questions. If a question is not 
something you have experienced, choose an answer based on similar experiences. 
 



















I can take several 
medications on 
different schedules











       
SEMMT002 
I can remember to 
take my medication 
as prescribed











       
SEMMT003 
I know when and 
how to take my 
medications











       
SEMMT004 
I can fit my 
medication 
schedule into my 
daily routine











       
SEMMT005 
I can follow 
directions when my 
doctor changes my 
medications











       
















 ................................  
       
SEMMT007 
I can get help when 
I am not sure how 
to take my 
medicine











       
SEMMT008 
I can remember to 
refill my 
prescriptions 
before they run out











       
SEMMT009 
I can remember to 
take my 
medications when 
there is no one to 
remind me











       
SEMMT010 
I can list my 
medications, 
including the doses 
and schedule











       
SEMMT011 
I can actively 
participate in 
decisions about my 
treatment











       
SEMMT012 
I can find 
information to 
learn more about 
my treatment











       
SEMMT013 
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SEMMT014 
I can work with my 
doctor to choose 
the treatment that 
seems right for me











       
 
 
CURRENT level of 
confidence… 
 
I am not 
at all 
confident 













I know what to do 
when my 
medication refill 
looks different than 
usual











       
SEMMT016 
I know what to do if 
I forget to take my 
medication(s)











       
SEMMT017 
I can use technology 
to help me manage 
my medication and 
treatments (for 




















I can continue my 
treatment when 
traveling











       
SEMMT019 
I can take my 
medication when I 
am working or away 
from home











       
SEMMT020 
I can take my 
medicine even if it 
causes mild side 
effects











       
SEMMT021 
I understand the 
difference between 
my symptoms and 
medication side 
effects











       
SEMMT022 
I can continue my 
treatment when I 
am not feeling well











       
SEMMT023 
I can take my 
medication when 
there is a change in 
my usual day 
(unexpected things 
happen)











       
SEMMT024 
I can figure out what 
treatment I need 



























 .................................  
       
SEMMT026 
















       
SEMMT027 
I can travel to my 
local pharmacy to 
fill my prescriptions
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